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Atherosclerosis is the underlying process of coronary heart disease, the leading cause of 
death in many developed countries including Australia. It is a chronic and multifactorial 
disease. There is convincing evidence that has established the link between atherosclerosis 
and postprandial hyperlipidaemia. The postprandial metabolism of dietary lipids can extend 
up to 8-10 h depending on dose. As breaks between meals are typically less than this, the 
efficiency of the metabolic machinery for processing these lipids becomes an important 
determinant of the exposure of arterial walls to pro-atherogenic lipoproteins. 
 The central paradigm of the current atherosclerosis model is the retention of 
remnant lipoproteins (chylomicrons and hepatic very low density lipoproteins (VLDL)) in the 
subendothelial space of arterial walls. Sustained concentrations of circulating remnant 
lipoproteins selectively bind to the subendothelial matrix and providing they are small 
enough will be retained in the subendothelial space. There is substantial evidence from cell 
lines, animal and human studies supporting the role of chylomicron particles on the 
development of atherosclerosis. Indeed the presence of apo B-48, a measure of 
chylomicron particle number, in the atherosclerotic tissue has been reported. 
 Chylomicrons are intestinally-derived lipoproteins that transport the absorbed 
dietary lipids to tissues expressing lipoprotein lipase (LPL). They are continuously secreted 
in various sizes depending on the fasting or postprandial state, triglyceride availability and 
apolipoprotein (apo) B-48 production rate. In the postprandial state, chylomicron particles 
tend to be larger in size to accommodate the increased flux of substrate absorbed (dietary 
triglyceride, cholesterol, phospholipids and fat soluble vitamins) instead of increasing the 
particle number. This highly efficient response is affected mainly by dietary fat ingestion 
(quantity and type of dietary fat). The dietary fatty acid composition has been recognised to 
modulate triglyceride-rich lipoprotein (TRL) response through their effect on lipid 
partitioning, chylomicron production and removal, and accessory factors. 
 Studies examining the effect of dietary fat on postprandial lipid metabolism do not 
directly measure the concentration of chylomicron particles in dense lipoprotein fractions. 
Rather, chylomicron lipid metabolism is mostly assessed by examining chylomicron particle 
number (apo B-48 or retinyl esters) in plasma or even indirectly as the concentration of 
triglyceride in less dense lipoprotein fractions (where small-sized pro-atherogenic remnants 
are not found). Moreover since the susceptibility to develop atherosclerosis differs 
individually either due to genetics or environmental factors, it is possible that there is an 
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interactive effect between dietary fats, genetic/metabolic determinants and chylomicron 
remnant metabolism. 
In the fasting state, triglyceride, LDL cholesterol and HDL cholesterol concentrations 
are generally utilised as markers for atherogenic risk. However we propose that these 
markers may not completely describe atherogenic risk. Different types of hyperlipidaemia 
exert different atherogenic risk despite having high triglyceride concentration. Similarly, 
HDL cholesterol does not represent cholesterol content in the remnant lipoproteins. 
Instead, non-HDL cholesterol captures the cholesterol content of remnant lipoproteins. 
Given the atherogenic evidence of remnants is abundant, studies investigating the 
association between chylomicron/apo B-48 and lipid parameters are limited and specific to 
the Japanese population. 
This thesis explores the association of apo B-48 concentration with metabolic and 
anthropometric parameters (Chapter 2), the atherogenic risk of hypertriglyceridaemia from 
the perspective of an involvement of remnant lipoproteins (explained in Chapter 3) and the 
acute effect of dietary fatty acid composition and metabolic determinants on postprandial 
chylomicron metabolism (explained in Chapter 4). 
The results of this study (Chapter 2) confirm previous evidence that fasting apo B-
48 concentration is strongly associated with triglyceride concentration. HDL cholesterol 
concentration was not associated with apo B-48 following gender and age adjustment. In 
subjects with MetS, who have higher basal apo B-48 concentration, the association and the 
contribution of triglyceride and non-HDL cholesterol on the variability of apo B-48 
concentration were increased compared to the non-MetS subjects. However these 
measures give no indication of chylomicron remnant homeostasis, which are our primary 
concern given the evidence of their atherogenicity.  
In Chapter 3, we demonstrated that normocholesterolemic subjects with 
hypertriglyceridemia exhibited an accumulation of small-sized chylomicron particles in 
fasting plasma. We suggest that this accumulation is due to a defect in catabolism and/or 
clearance of those particles rather than as a result of increased chylomicron production. 
The insulin resistant state of the hypertriglyceridaemic subjects in this study may contribute 
to the defective catabolism and uptake of remnants by the liver. Our findings further 
substantiate the role of chylomicron remnants in mechanisms leading to the increased risk 
of CVD in hypertriglyceridemic subjects. 
Contrary to the conventional thought, the results of Chapter 4 showed that in 
normotriglyceridaemic subjects, the majority of chylomicron particles in the fasting state 
and their postprandial response are observed within the potentially pro-atherogenic Sf <20 
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fraction. This suggests that following dietary fat ingestion, a substantial proportion of 
circulating chylomicrons can directly enter the arterial walls.   
We also observed that the magnitude of postprandial hyper-remnantaemia is 
dependent both on the nature of dietary fatty acids ingested and genetic determinants. We 
also identified a subset of subjects in this group who despite being normotriglyceridemic in 
the fasting state exhibit elevated postprandial triglyceride (hyper-responders (HR)). The HR 
exhibited a substantial accumulation of chylomicron remnants following consumption of a 
palm oil rich meal but that this feature was not observed in the normo-responders. We 
postulate that differential expression of key apolipoproteins (i.e. apo C-II, apo C-III, apo E) 
or a modest hydrolytic defect in muscle tissue may contribute to this differential response. 
The classical markers of plasma lipid homeostasis give no valuable insight into chylomicron 
metabolism, remnant homeostasis and the atherogenic risk.  
The findings presented in this thesis provide more insight into the potential 
mechanisms of increased atherogenic risk in individuals with impaired triglyceridaemia and 
the interactive effect of the type of dietary fatty acid composition and genotype/metabolic 
determinants on chylomicron remnant response. Triglyceride concentration, LDL 
cholesterol and HDL cholesterol are not suitable surrogate markers for chylomicron 
remnant metabolism and atherogenicity. Our findings reiterate the importance of assessing 
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Introduction and Structure of Thesis 
 
Background 
Coronary heart disease, the most common form of CVD, is the leading cause of death in 
Australia in 2011 (AIHW 2014). The increase in the prevalence of coronary heart disease has 
put a considerable strain on the public health system (financial and functional). Imbalanced 
diets play an important role in this problem. This includes consumption of high fat content 
food. To prevent or treat coronary artery disease, dietary guidelines since 1960s have 
emphasised a reduction in the consumption of food rich in saturated fat (Page, Allen et al. 
1961). The quantity and the quality of dietary fats have been an ongoing issue in 
cardiovascular health. 
In the well developed countries and those who have experienced an economic 
surge, access to food is not an issue. Consequently humans spend most part of the day in a 
postprandial state. Since lipid metabolism takes longer than carbohydrate and proteins, this 
places a greater burden on the metabolic machinery of the human body and poses more 
atherogenic lipoprotein exposure on the vascular walls. In 1979, Zilversmit introduced the 
idea that atherogenesis was indeed as a postprandial phenomenon (Zilversmit 1979), and 
since then the metabolism of triglyceride-rich lipoprotein (TRL) has been investigated 
extensively.  
Chylomicrons are lipoprotein particles originating from the intestine. They carry the 
absorbed dietary lipids and enter the circulation compartment via the thoracic duct. 
Nascent chylomicrons are secreted in various sizes depending on the lipidation. In the 
circulation, chylomicron particles undergo lipolysis by LPL and exchange apolipoprotein 
contents and substrate (triglyceride and cholesteryl ester) with HDL particles. Following 
lipolysis, chylomicrons shed their lipid content leaving smaller remnants. Chylomicron 
remnants with their remaining lipid content then enter the liver for clearance. Remnants 
will be removed by hepatocytes predominantly through receptor-mediated pathways: LDL 
receptor, LDL receptor related proteins (LRP) after acquiring additional apo E, and heparan 
sulphate proteoglycans (HSPG) mediated by apo E, LPL and hepatic lipase (HL) (Fujioka and 
Ishikawa 2009). When their removals were delayed, a build-up of cholesterol-rich remnants 
would ensue. 
 The current atherogenesis model describes that the initiator of atherogenesis is 
subendothelial retention of cholesterol rich lipoproteins (Williams and Tabas 1995; Williams 
and Tabas 2005). Endothelium is a simple squamous epithelium lining the inner part of 
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cardiovascular system with a very tight connection between cells (Simionescu and 
Simionescu 1991). It separates two fluid compartments, plasma and interstitial fluid. The 
luminal side of endothelial membrane is continuously being exposed to circulating cells and 
plasma containing macromolecules, solutes and water.  
Lipoprotein particles are transported across the artery walls via plasmalemmal 
vesicles by a highly active transport system (Simionescu and Simionescu 1991; Dallinga-
Thie, Kroon et al. 2016). Only lipoproteins sized less than 70 nm in diameter, Sf 12 – 60 
fraction or less may enter the artery walls (Stender and Zilversmit 1981; Shaikh, Wootton et 
al. 1991; Simionescu and Simionescu 1991; Zilversmit 1995). The entrance and retention of 
lipoprotein particles in the subendothelial tissue depends on the sustained lipoprotein 
plasma concentration, particle size and the selectivity of lipoprotein to bind with 
subendothelial matrix. A line of evidence has demonstrated the ability of chylomicron 
remnant entering and being trapped in subendothelial tissue (Mamo 1995; Proctor and 
Mamo 1996; Fujioka, Cooper et al. 1998; Proctor, Vine et al. 2002). Once chylomicron 
remnants are trapped in the subendothelial matrix, they can induce monocyte activation 
and the formation of lipid-laden macrophages (Botham and Wheeler-Jones 2013). Indeed 
apo B-48, a measure of chylomicron particle number, has been detected in atherosclerotic 
tissue in animal model and humans (Proctor and Mamo 1996; Pal, Semorine et al. 2003; 
Proctor and Mamo 2003; Nakano, Nakajima et al. 2008).  
 Despite that chylomicron remnant atherogenicity are evident, increased 
triglyceride and low HDL cholesterol concentrations are still utilised as markers for 
atherogenicity. Studies investigating the association between apo B-48 and other lipid 
parameters are limited and the subjects are specific to the Japanese population. 
Atherosclerosis is a chronic condition and a multifactorial disease. Thus it requires a 
certain amount of time from retention of cholesterol-rich lipoprotein in the subendothelial 
matrix to develop atheroma lesion. Findings from an autopsy study on children and young 
adults with the cause of death non-cardiac suggested that subendhothelial retention has 
started as diffuse intimal thickening and occurs long before it become pathologic 
(Nakashima, Fujii et al. 2007; Tabas, Williams et al. 2007).  
Dietary fatty acid composition has been recognised to implicate chylomicron 
metabolism at chylomicron assembly, hydrolysis, and clearance (Williams 1998; Williams, 
Bateman et al. 2004). However studies examining chylomicron response in the dense 
fraction are very limited as most of those studies measured chylomicron/triglyceride/retinyl 
esters in the lipid-rich fraction, a fraction consisted of large-sized lipoproteins which are less 
likely to penetrate the intimal membrane. Since the susceptibility to develop 
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atherosclerosis differs individually either due to genetics or environmental factors (Tabas, 
Williams et al. 2007), it is possible that dietary fats exert differential effect.  
 The observational statements which have provided the foundation for this PhD 
proposal are that: 
1) CVD is the leading cause of death in Australia; 
2) Exaggerated postprandial lipemia contributes to the development of 
atherogenesis; 
3) Apo B-48 containing remnants can penetrate and be retained in the 
subendothelial matrix; 
4) The findings of the effect of dietary fatty acid on postprandial remnants are 
limited and inconsistent; 
5) The susceptibility to develop exaggerated remnant metabolism varies between 
individuals. 
Hence the above arguments lead to the following hypothesis. 
   
Hypothesis  
Hypothesis 1: Apo B-48 concentration and their size distribution are associated with 
metabolic and anthropometric parameters in fasting. 
 
Hypothesis 2: Dietary fats differentially affect chylomicron remnant metabolism in 
otherwise healthy normolipidaemic subjects. 
 
Objectives 
Objective 1: To explore the associations of apo B-48 concentration with metabolic and 
anthropometric parameters. 
 
Objective 2: To examine the abundance and size distribution of chylomicron particles in 
individuals with and without hypertriglyceridaemia 
 
Objective 3: To investigate the acute effect of dietary fatty acid composition and 







Chapter 1: Literature review 
This chapter provides a comprehensive review of the evidence to date on the role of 
chylomicrons and their putative role in postprandial dyslipidaemia leading to 
atherosclerosis, specifically the postprandial response in the triglyceride-deplete fraction. 
The literature review established the foundation of my hypothesis and objectives. 
 
Chapter 2: The association of fasting chylomicron concentration with a range of 
anthropometric and lipid parameters:  A cross-sectional study 
Thesis objective addressed in this chapter: 
Objective 1: To explore the associations of apo B-48 concentration with metabolic and 
anthropometric parameters. 
 
Content of this chapter is covered by the manuscript: 
Irawati D, Mamo JCL, Dhaliwal SS, Soares MJ, Slivkoff-Clark KM, James AP (2016). Plasma 
triglyceride and an inverse association with high-density lipoprotein cholesterol are poor 
surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with 
the metabolic syndrome. Lipids in health and Disease, In press. 
 
Chapter 3: Chylomicron size distribution in subjects with and without 
hypertriglyceridaemia 
Thesis objective addressed in this chapter: 
Objective 2: To examine the abundance and size distribution of chylomicron particles in 
individuals with and without hypertriglyceridaemia 
 
Content of this chapter is covered by the article: 
Irawati D, Mamo JCL, Soares MJ, Slivkoff-Clark KM, James AP (2015). Hypertriglyceridemic 
subjects exhibit an accumulation of small dense chylomicron particles in the fasting state. 
Atherosclerosis, 243(1), 236-241. 
 
Chapter 4: The effect of dietary fatty acid composition on plasma abundance of pro-
atherogenic chylomicron remnants in postprandial lipaemia 
Thesis objective addressed in this chapter: 
Objective 3: To investigate the acute effect of dietary fatty acid composition and metabolic 




Content of this chapter is covered by the article: 
Irawati D, Mamo JCL, Soares MJ, Slivkoff-Clark KM, James AP. Dietary fat and genetic 
determinants of plasma chylomicron remnant homeostasis in normolipidemic subjects: 
Insight into atherogenic risk (2017). British Journal of Nutrition, In press. 
 
Chapter 5: Discussion, limitation and future studies 
This chapter provides a comprehensive discussion of chapter 2, chapter 3 and chapter 4, 












































ABCA ATP binding cassette transporter 
ABCG ATP binding cassette subfamily G 
Apo Apolipoprotein 
AUC Area under curve 
BMI Body mass index 
CD Cluster of differentiation 
CETP Cholesteryl ester transfer protein 
COP Coat protein complex 
CRP C-reactive protein 
CVD Cardiovascular disease 
DGAT Diacylglycerol acyltransferase 
ELISA enzyme-linked immunoabsorbent assays 
FABP Fatty acid binding protein 
FATP Fatty acid transport protein 
GLP Glucagon-like peptide 
HDL High density lipoprotein 
HL Hepatic lipase 
HOMA-IR Homeostasis model of insulin resistance 
HSPG Heparan sulphate proteoglycan 
HTG Hypertriglyceridaemic 
IAUC Incremental area under curve 
IDL Intermediate density lipoprotein 
IL Interleukin 
LCAT Lecithin-cholesterol acyltransferase 
LDL Low density lipoprotein 
LDLR Low density lipoprotein receptor 
LMF Lipase maturation factor 
Lp(a) Lipoprotein(a) 
LPL Lipoprotein lipase 




MCP Monocyte chemo-attractant protein 
MGAT Monoacylglycerol acyltransferase 
MetS Metabolic syndrome 
mRNA Messenger ribonucleic acid 
MUFA Mono-unsaturated fatty acid 
MTP Microsomal transfer protein 
NCEP-ATP National Cholesterol Education Program Adult Treatment Panel 
NEFA Non-esterified fatty acid 
NPC1L1 Niemann Pick C1-like1 
NTG Normotriglyceridaemic 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PCTV Pre-chylomicron transport vesicles 
PUFA Poly-unsaturated fatty acid 
RLP Remnant-like protein 
SAD Sagittal abdominal diameter 
Sar1b Secretion associated Ras related GTPase 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SREBP Sterol regulatory element binding proteins 
SE Standard error 
Sf Svedberg flotation rate 
SFA Saturated fatty acid 
SULF2 Sulfate glucosamine 6-O-endosulfatase-2 
TRL Triglyceride-rich lipoprotein 
VAMP vesicle-associated membrane protein 
VLDL Very low density lipoprotein 
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Chapter 1: Literature review 
 
1.1 Introduction 
Increasing rates of obesity and the growing risk for MetS and CVD necessitate a greater 
understanding of the mechanisms involved in the development of atherosclerosis. This 
chapter presents a detailed review of the evidence to date on the role of chylomicron in 
atherosclerosis in relation to dietary fats particularly postprandial response in the dense 
fraction. This chapter outlines the potential mechanism of chylomicron remnant 
accumulation and the possibility of differential effect of dietary fats in different metabolic 
phenotype. This chapter also points out the importance of measuring chylomicron (apo B-
48) concentration as a potential surrogate marker for atherogenicity. 
    
1.2 Chylomicron structure 
Chylomicrons are the largest circulating lipoprotein particles. Previously it was thought that 
chylomicrons were only present in circulation as large lipid rich particles and that they were 
mostly secreted following consumption of lipid containing meals. However there is now 
evidence that chylomicrons are continuously secreted in various sizes depending on the 
fasting or postprandial state, triglyceride availability (type and amount) and apolipoprotein 
(apo) B-48 production rate (Guo, Kohen Avramoglu, & Adeli, 2005; Hayashi et al., 1990; 
Zheng, Ikewaki, Walsh, & Sacks, 2006). Chylomicrons are spherical in shape containing: 
triacylglycerol (85-92%), phospholipids (6-12%), cholesterol (1-3%) and proteins (1-2%) 
(Frayn, 2009; Hussain et al., 1996). The molecules within lipoprotein particles are bound by 
non-covalent forces like other emulsion particles (Mills, Lane, & Weech, 1984).  
Chylomicron particles consist of a core of hydrophobic materials which is 
surrounded by a hydrophilic monolayer envelope. The core contains of triglyceride and 
cholesteryl esters whereas the envelope is composed of phospholipids, free cholesterol and 
a mixture of specific proteins (i.e. apo B-48, apo A, apo C and apo E). These apolipoproteins 
are important for the structural integrity, functionality, scavenger receptor binding for 
lipoprotein particles and to act as cofactors or inhibitors for lipase activity and removal. The 
structural components of chylomicrons (apolipoprotein and substrate composition) 
influence lipolysis and remnant removal from the circulation. 
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 Apo B-48 is the main apolipoprotein in chylomicrons synthesised by the enterocyte 
of small intestine, it does not interchange with other lipoproteins, and hence is a marker of 
chylomicron particles (Dash, Xiao, Morgantini, & Lewis, 2015). It serves as a structural 
protein essential for chylomicron assembly. In humans, apo B-48 is a translational product 
of the apo B gene located in chromosome 2 in human genome (Huang, Miller, Bruns, & 
Breslow, 1986; Hussain et al., 1996; Kane, Hardman, & Paulus, 1980). It is formed by post-
transcriptional editing of apo B mRNA with a premature stop due to the conversion of 
codon 2153 from CAA (coding for glutamine) to UAA (a stop signal) by cytidine deaminase 
in the ribosomes (Powell et al., 1987). The conversion of C to U is mediated by a 
heterodimeric complex of apobec-1, an RNA-specific cytidine deaminase highly expressed 
in the small intestine in humans (Anant & Davidson, 2001; Giannoni et al., 1995; 
Hadjiagapiou, Giannoni, Funahashi, Skarosi, & Davidson, 1994) (Figure 1). This leads to the 
translation of a truncated apo B containing 48% of mature apo B primary sequence. 
Consequently apo B-48 does not contain the C-terminal portion of apo B which affects its 
interaction with hepatic uptake receptors (Marcel et al., 1987). 
 
Figure 1. Apo B-48 as a result of m-RNA editing of apo B. Apo B-48 is produced from the C 
to U editing of nuclear apo B transcript. This reaction requires an 11-nucleotide cassette 
(UGAUCAGUAUA) known as mooring sequence, an AU-rich context and the presence of 
distal efficiency element 5’ and 3’ of the edited C (asterisked). It is proposed that the region 
flanks the edited C forming a stem loop structure. The apo B m-RNA editing complex 
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comprises of apobec-1 homodimer and auxiliary proteins known as complementation 
factors.  
Source: Adaptation from Figure 1, (Davidson & Shelness, 2000) (permission not required) 
1.3 Chylomicron metabolism 
Chylomicrons are lipoproteins that transport dietary fat including lipids and fat soluble 
vitamins absorbed in the enterocytes. The process by which chylomicrons deliver these 
substrates from enterocytes to target tissues is a multistep and complex process.  
 Briefly chylomicrons are assembled in the enterocytes which involved synthesis of 
apo B-48 and lipidation of the primordial particles mediated by microsomal transfer protein 
(MTP), an endoplasmic reticulum-associated chaperone with the main role transferring 
neutral lipids (triglyceride, phospholipids and cholesterol ester) to the nascent apo B 
containing lipoproteins. Nascent chylomicrons are then secreted into the intestinal lymph 
and move towards the thoracic lymph duct.  Once they enter plasma, chylomicrons interact 
with other lipoprotein particles exchanging apolipoproteins and undergo remodelling. 
Together with hepatic derived VLDL, chylomicrons constitute triglyceride-rich lipoproteins 
(TRL). Their triglyceride contents are transferred to the target tissues facilitated by 
lipoprotein lipase (LPL), an enzyme responsible for hydrolysing triglyceride. Following 
shedding their lipid contents, eventually chylomicrons shrink and become chylomicron 
remnants rich in cholesteryl ester. Remnants are then removed by hepatocytes 
predominantly through a receptor-mediated pathway. The details of the process are 
explained below. 
1.3.1 Chylomicron assembly 
The current model of chylomicron assembly indicates the presence of apo B-48 and MTP as 
obligate requirements. This process consists of apo B-48 synthesis and sequential addition 
of triglyceride to the primordial particle by the action of MTP (Hussain, 2000; C. M. 






Figure 2. Apo B-MTP binding in lipoprotein assembly. The image shows the possible 
pathways of lipoprotein lipidation mediated by MTP. i) Free MTP binds to apo B. This 
process involves lipid extraction in endoplasmic reticulum membrane and pocket formation 
of apo B which serves as lipid nucleation site. ii) MTP associated with lipid droplets bind to 
apo B. Apo B would encircle and wrap around the MTP-lipid droplet complex resulting in an 
efficient lipidation.  
Source: Adaptation from Figure 2B, (Hussain, Shi, & Dreizen, 2003)(permission not required) 
During translation apo B is translocated across the rough endoplasmic reticulum 
membrane into the lumen of endoplasmic reticulum (Fisher & Ginsberg, 2002; Pariyarath et 
al., 2001). As shown in Figure 2, in the presence of triglyceride, the NH2 terminus of apo B 
interacts with MTP, a soluble heterodimer of 97 kDa catalytic subunit and protein 
disulphide isomerase, producing an optimal folding of apo B. MTP binds to a donor 
membrane and extracts triglyceride molecules. The MTP containing the bound lipid then 
detaches from the membrane and shuttles the triglyceride molecules from endoplasmic 
reticulum membrane to apo B-48-containing lipoprotein resulting in the formation of a 
primordial chylomicron (Atzel & Wetterau, 1993; Dash et al., 2015).  
Apo B-48 is synthesised constitutively however the size of chylomicron will depend 
on the amount of lipid transported. Unlipidated apo B-48 is misfolded and degraded via an 
endoplasmic reticulum associated degradation pathway, autophagy (Fisher & Williams, 
2008) or proteosomal pathway (Fisher & Ginsberg, 2002; Fisher et al., 2001). However 
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inadequately lipidated intestinal apo B is less susceptible to degradation than hepatic apo 
B. Enterocytes are able to secrete apo B-48 containing lipoproteins as lipid-poor HDL-sized 
particles in the absence of dietary fat availability or storing apo B-48 in apical pool to be 




Figure 3. Chylomicron assembly.  
Source: Adaptation from Figure 1, (Black, 2007) (permission not required) 
In the second step of chylomicron assembly, facilitated by MTP, the primordial 
chylomicron continues to undergo lipidation by the fusion of endoluminal lipid droplets 
with primordial chylomicrons in the endoplasmic reticulum (Figure 3). The lipid droplets are 
composed of neutral lipids (triglyceride and cholesteryl ester) in the core surrounded by 
monolayer of phospholipids. The triglyceride is formed from dietary fatty acid and 
monoacylglycerol (MAG) mediated by monoacylglycerol acyltransferase (MGAT) and 
diacylglycerol acyltransferase (DGAT) respectively (Yen, Stone, Koliwad, Harris, & Farese Jr, 
2008). The triglyceride products of DGAT reaction are extracted from endoplasmic 
reticulum membrane by MTP and being packed into the cores of cytosolic lipid droplets 
(Atzel & Wetterau, 1993; Yen et al., 2008). These lipid droplets incorporate with primordial 
chylomicrons allowing them to undergo progressive lipid engorgement.  
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Apo A-IV is added at this stage to maintain surface stability (Lu et al., 2006) (Figure 
3). Apo A-IV is mainly synthesised in the enterocytes (Pan & Hussain, 2012). It has been 
suggested that apo A-IV stimulates pre-chylomicrons to grow larger by stabilising the 
expanded lipid/aqueous interface during lipoprotein assembly (Lu et al., 2006) and hence 
implicates apo A-IV incorporation into primordial chylomicrons at an early stage (F. Wang et 
al., 2015). 
As shown in Figure 3, once the lipidation is complete, the nascent pre-chylomicrons 
are transported for secretion through the Golgi apparatus in the form of pre-chylomicron 
transport vesicles (PCTV). It consists of coat protein complex (COP) II, apo B-48, CD36, 
FABP-1 and vesicle-associated membrane protein-7 (VAMP7) (Mansbach & Siddiqi, 2010; 
Shahzad Siddiqi et al., 2010). The synthesis of PCTV and its budding from endoplasmic 
reticulum is initiated by FABP-1, a part of cytosolic protein complex consisting of Sar1b, 
Sec13 and small valosin-containing protein/p97 interactive protein (Dash et al., 2015). The 
FABP-1 complex are then released from endoplasmic reticulum after Sar1b underwent 
phosphorylation mediated by protein kinase C-zeta (S. Siddiqi & Mansbach Ii, 2012). Then 
they form a vesicular complex budding from endoplasmic reticulum which fuses with the 
cis-Golgi membrane by the interaction of VAMP7 with the Golgi membrane proteins (S. A. 
Siddiqi et al., 2006). 
At this stage, pre-chylomicrons undergo maturation and receive apo A-I. Apo A-I is  
synthesised in enterocytes (Rachmilewitz, Albers, Saunders, & Fainaru, 1978). Suppression 
of apo A-I did not lead to a reduction in the release of triglyceride from enterocytes 
indicating that apo A-I may not be required in chylomicron lipidation (Jaschke et al., 2012). 
Therefore it is suggested that the attachment of apo A-I to chylomicrons occurs after 
chylomicron lipidation. Eventually chylomicrons will be secreted as a mature, nascent 
chylomicron particles into the pericellular space adjacent to lymphatic fenestrae and then 
enter the circulation at the thoracic duct (Abumrad & Davidson, 2012). 
        
1.3.2 Chylomicron lipolysis and clearance 
Once chylomicrons enter plasma, apo A-I dissociates rapidly (Vigne & Havel, 1981) and they 
further receive apo C, in particular apo C-II which is important for their lipolysis (Patsch, 
1987). Apo C-II is mainly synthesised in the liver and to some extent in enterocytes. It is 
found bound to chylomicrons, hepatic origin TRL, LDL and HDL. The C-terminal helix of apo 
C-II is important for interaction with LPL and is required for maximal lipolysis of TRL (Kei, 
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Filippatos, Tsimihodimos, & Elisaf, 2012). Apo C-II guides chylomicrons to the active site of 
LPL in the surface of endothelial cells (Kei et al., 2012; LaRosa, Levy, Herbert, Lux, & 
Fredrickson, 1970; Zdunek et al., 2003). The interaction between apo C-II, LPL and TRL 
involves changes in lipoprotein surface pressure and apo C-II conformational structure 
(Meyers, Larsson, Olivecrona, & Small, 2015). The interaction between chylomicrons, LPL 
and apo C-II requires the presence of apo A-IV. The absence of apo A-IV has been reported 
to delay chylomicron hydrolysis. As a result, chylomicrons from apo A-IV deficient mice 
were found to be larger in size and were cleared more slowly from circulation (Kohan et al., 
2012). The mechanism behind this could be that the loss of the ability of apo A-IV to 
modulate apo C-II, an activator of LPL (Goldberg, Scheraldi, Yacoub, Saxena, & Bisgaier, 
1990). 
LPL hydrolyses the triglyceride content of the bound chylomicrons resulting in the 
release of fatty acid. The fatty acids are then taken up by CD36 located on the plasma 
membrane of endothelial cells mainly in adipose and muscle tissue (Figure 4). LPL is a 
member of a triglyceride gene family consisting of 2 distinct domains, the amino-terminus 
domain and the smaller carboxyl-terminus domain (H. Wang & Eckel, 2009). The amino-
terminus domain contains the catalytic triad which is important for lipolysis. The carboxyl-
terminal domain contains the heparin-binding domain, possibly an important feature for 
binding lipoprotein. It is synthesised in adipocytes and striated myocytes and the synthesis 
is regulated by fasting and postprandial states. Following synthesis, LPL is matured by LMF1 
and then secreted into the subendothelial space. LPL then binds to HSPG of the endothelial 
cells membrane and trancytosed to the luminal membrane of endothelial cells. Once LPL 
reaches the luminal surface, LPL is anchored by GPIHBP1 probably in lipid rafts together 
with syndecan 1 and a fatty acid transporter CD-36 (Geesje M. Dallinga-Thie et al., 2010; K. 
J. Williams, 2008).  
LPL activity is influenced by the presence of apo C-III. As chylomicrons pass through 
circulation, they pick apo C-III from HDL or VLDL particles (Cohn, Marcoux, & Davignon, 
1999; C. Xiao et al., 2011).  Apo C-III inhibits LPL activity by interfering the binding of LPL to 
lipids (Julve, Martín-Campos, Escolà-Gil, & Blanco-Vaca, 2016).  
After hydrolysis by LPL, the size of chylomicrons reduces. Phospholipids are 
transferred to HDL particles and unesterified cholesterols move from the core to the 
surface of the particles (Changting Xiao & Lewis, 2012). At this stage, they become 
chylomicron remnants with a high cholesteryl ester level, lysophosphatidylcholine, apo B-48 
and apo E. The presence of apo E in chylomicron remnants is important as it mediates 
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hepatic recognition of remnant lipoproteins and their uptake (Blum, 1982). Remnant 
particles become smaller in size and denser. Chylomicron remnants continue to circulate 
until they are removed from the circulation primarily by the liver.  
Apolipoprotein transfer from HDL to chylomicrons can be altered by the 
overexpression apo A-II. Apo A-II is mainly produced in the liver and to a smaller extent in 
the intestine. It has been demonstrated that overexpression of human apo A-II in mice 
induces postprandial hypertriglyceridemia (Boisfer et al., 1999). This overexpression altered 
the exchange of other apolipoproteins from HDL (i.e. apo C-II, apo C-III and apo E) which 
may affect chylomicron clearance. 
 
 
Figure 4. Hydrolysis of TRL. The image shows the sequential lipolytic stages from secretion 
of LPL in parenchymal cells (adipocytes or myocytes) to the binding of LPL anchored by 
GPHIHBP1 to chylomicron particles in the luminal membrane of endothelial cells. 
Source: Adaptation from Figure 4, Dallinga-Thie et al 2010) (Licence number: 3934120991374). 
After entering the liver compartment, chylomicron remnants flow into the liver 
sinusoids. To enter the space of Disse, chylomicron remnants must pass through the 
fenestrated endothelium in the liver. These fenestrae serve as a gate function for filtering 
lipoproteins. The circulating remnants are removed in the liver through several pathways 
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(Cooper, 1997). The first pathway is direct receptor-mediated uptake remnants. Facilitated 
by apo E, remnants bind to the heparan sulphate proteoglycans located on hepatocyte 
surface and then undergo internalisation mediated by a receptor-mediated pathway: low 
density lipoprotein (LDL) receptor and LDL receptor related proteins (LRP) (Fujioka & 
Ishikawa, 2009). LDL receptors likely accommodate the removal small remnants from the 
circulation whereas large remnants are likely to be cleared by the liver involving HSPG 
(Windler et al., 1996). The removal of remnants via LDL receptor can be categorized as 
either low capacity (≤5x104 binding sites per hepatocyte) or high affinity leading to rapid 
endocytosis (Stanford et al., 2009) with t1/2 of about 10 minutes (M. S. Brown & Goldstein, 
1986; K. J. Williams, 2008). Animal studies comparing wild type versus LDLR deficient livers 
in vivo have shown that in LDLR null livers, despite being rapidly cleared from the 
circulation by the liver, remnant lipoproteins stayed in the space of Disse longer (minimal 
20 minutes), a contrast feature compared to the wild type livers. In the wild type livers, no 
remnant lipoproteins were found in the space of Disse. Instead the remnants promptly 
undergo endocytosis through LDL receptor pathway (Mortimer, Beveridge, Martins, & 
Redgrave, 1995). In addition to LDL receptor mediated clearance, LRP is also importance in 
chylomicron remnant clearance. Chylomicrons can be cleared through LRP1 via its 
interaction with apo E (Lillis, Van Duyn, Murphy-Ullrich, & Strickland, 2008). The binding of 
remnant lipoprotein and apo E to hepatic receptor is altered by apo C-III leading to the 
reduced remnant clearance via receptor mediated endocytosis (Sacks, 2015). 
Remnant lipoproteins are also removed through sequestration mediated by 
syndecan1 HSPG by interacting with LPL, hepatic lipase and apo E bound to remnant 
particles HSPG (Cooper, 1997; K. J. Williams & Chen, 2010). This pathway has been 
suggested to remove large remnants (Nakajima et al., 2014; Windler et al., 1996). The 
syndecan pathway is categorized as high capacity (>106 lipoprotein binding sites per 
hepatocyte) and medium affinity leading to slower rate of endocytosis with t1/2 of about 1 
hour (Stanford et al., 2009; K. J. Williams, 2008). Apo A-V affects the removal of 
chylomicron from the circulation by a mechanism involving complex interactions between 
apo A-V and LPL, proteoglycans and GPIHBP1 (Nilsson, Heeren, Olivecrona, & Merkel, 
2011). 
 The ability to clear chylomicron remnants via a number of pathways indicates the 
importance of remnant clearance mechanism in maintaining lipoprotein homeostasis and 




1.3.3 Chylomicron regulation 
As mentioned previously, chylomicrons are produced continuously by enterocytes 
irrespective of the fasting or postprandial state (Guo et al., 2005). In the postprandial state, 
chylomicron particles tend to be larger in size to accommodate the increased flux of 
substrate absorbed (dietary triglyceride, cholesterol, phospholipids and fat soluble 
vitamins). The increase in chylomicron number is relatively small (Hayashi et al., 1990). This 
highly efficient response is affected mainly by dietary fat ingestion however other factors 
such as paracrine and systemic factors also hold a crucial role in all stages of chylomicron 
metabolism. This section will discuss some factors regulating chylomicron metabolism that 
is associated with the study objectives.  
 
1.3.3.1 NEFA 
Circulating NEFA has been shown to affect chylomicron production. A kinetic study 
examining the effect of a short term elevation in plasma NEFA on human intestinal and 
hepatic TRL production revealed a 69% and 39% increase in the rate of production of apo B-
48 and apo B-100 containing TRL but no effect was observed on the catabolic rate (Duez et 
al., 2008). Similar findings were also observed in an animal study (Lewis et al., 2004). 
Elevated NEFA concentration, as a result of overproduction of hepatic NEFA and a 
decreased NEFA sequestration capacity of adipose tissue, is commonly observed in various 
metabolic states such as insulin resistance and type-2 diabetes (Lewis, 1997; Lewis, 
Carpentier, Adeli, & Giacca, 2002). However the mechanism by which elevated NEFA 
impacts chylomicron production remains debatable. It is proposed that increased NEFA 
concentration may promote lipoprotein production through increased pool size of NEFA 
/triglyceride in the enterocyte due to elevated substrate availability (Changting Xiao & 
Lewis, 2012), stabilization of intracellular apo B and decreased degradation (Lewis et al., 
2004). Tracer studies conducted in pancreatectomised dogs on fat-free diets have 
suggested that the circulating non-dietary NEFA enter enterocytes, undergo esterification 
and are secreted into the circulation as chylomicrons (Steiner, Poapst, & Davidson, 1975).     
      
1.3.3.2 Insulin 
1.3.3.2.1  Effect of insulin on chylomicron production 
Substantial evidence has demonstrated the inhibitory effect of insulin on chylomicron 
production in conditions where an intact insulin signalling pathway is maintained. Studies 
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using human foetus jejunal explants have demonstrated an inhibition of the secretion of 
apo B-48 containing lipoproteins following insulin exposure (Levy et al., 1996). This finding 
is supported by fasting and postprandial in vivo studies showing that during acute 
hyperinsulinemia induced by the euglycemic-hyperinsulinemic clamp chylomicron 
production was suppressed (Harbis et al., 2001; Pavlic, Xiao, Szeto, Patterson, & Lewis, 
2010). The mechanism by which chylomicron production is suppressed by insulin remains 
to be completely elucidated. It has been suggested that insulin exerts its effects at the co- 
or post-translational level of apo B as insulin did not affect apo B mRNA level (Levy et al., 
1996). Under hyperinsulinemic, euglycaemic clamp conditions Pavlic et al (2010) reported a 
reduced circulating NEFA concentration suggesting that  insulin may also act partly through 
the inhibition of the lipolysis of stored triglyceride in adipose and extra-hepatic tissues 
(Pavlic et al., 2010). However it is likely that insulin also affects apo B-48 production of 
other means since suppression of NEFA release by Intralipid and heparin infusion altered 
the rate of apo B-48 production.  
In insulin resistant conditions such as type-2 diabetes and metabolic syndrome, the 
insulin-mediated inhibition of chylomicron production is blunted resulting in an 
overproduction of chylomicron particles (Federico, Naples, Taylor, & Adeli, 2006; Nogueira 
et al., 2012). Kinetic studies in humans have demonstrated an increased rate of 
chylomicron production in type-2 diabetes (Hogue et al., 2007) and in insulin resistance 
(Duez et al., 2006). It has been proposed that in the insulin resistant state, protein tyrosine 
phosphatase-1B, extracellular signal-related kinase and sterol regulatory element-binding 
protein-1c pathway, and MTP gene transcription are activated, leading to increased stability 
of intracellular apo B-48 and de novo lipogenesis  (Au, Kung, & Lin, 2003; Federico et al., 
2006; Haidari et al., 2002). It was also found that NPC1L1 (a regulator of cholesterol 
absorption) and MTP expression were increased in duodenal biopsies from type-2 diabetes 
patients. This was thought to be due to a down-regulation of the cholesterol homeostasis 
regulators ABCG5 and ABCG8 which send cholesterol back into the intestinal lumen, 
increasing substrate availability (triglyceride and cholesterol) for chylomicron assembly 
(Lally, Tan, Owens, & Tomkin, 2006). Insulin also plays a role in the routing of pre-
chylomicrons from the endoplasmic reticulum to the golgi apparatus. Insulin resistant mice 
exhibit alteration in pre-chylomicron routing from endoplasmic reticulum to the Golgi due 





1.3.3.2.2 Effect of insulin on lipolysis 
Once entering the plasma compartment, chylomicrons undergo lipolysis mediated by LPL. 
Insulin acts to increase LPL activity by a number of mechanisms (Sadur & Eckel, 1982). 
Insulin directly increases LPL activity via its stimulation of the transcription of the LPL gene. 
Hence in subjects with insulin resistance this leads to a diminished LPL activity and 
consequently delayed clearance from circulation (Maheux, Azhar, Kern, Chen, & Reaven, 
1997). In addition subjects with type-2 diabetes have been found to have a lower adipose 
LPL activity both in fasting and postprandial states (Annuzzi et al., 2008). Insulin also 
modulates LPL activity through inhibition of apo C-III expression which would consequently 
result in increased LPL activity (Altomonte et al., 2004). 
 
1.3.3.2.3 Effect of insulin on chylomicron clearance 
Insulin affects the rate of chylomicron clearance in the liver. Insulin promotes LDLR gene 
expression via activation of the sterol regulatory element binding proteins (SREBP) 1 signal 
transduction pathway (Streicher et al., 1996). Insulin may also affects LDLR expression via 
upregulation of PCSK9, a key regulator of hepatic LDLR degradation (Ferri & Ruscica, 2016). 
Insulin induced upregulation of PCSK9 through activation of SREBP-1c transcription factor. 
Indeed subjects with insulin resistance exhibit decreased LDLR expression which would 
result in a delayed clearance of chylomicron remnants. Insulin also plays a role in the 
clearance of chylomicron remnants via modulation of HSPG structure. In subjects with 
insulin resistance, over-expression of hepatic SULF2 results in an increased degradation of 
matrix HSPG (Chen et al., 2009). Taken together these findings suggest that in the insulin 
resistant state, a general increase in chylomicron concentration in circulation possibly with 
a build-up of cholesterol-rich chylomicron would be found. 
 
1.3.3.3 Dietary fat 
Both the amount and type of fat consumed affect the postprandial chylomicron response. 
Consumption of increasing amounts of fat results in a proportional increase in the 
postprandial triglyceride and chylomicron response (Cohen, Noakes, & Benade, 1988; 
Dubois et al., 1998; Anthony P. James & John C. Mamo, 2012). However consumption of 
low amounts of fat (<15 g) do not result in an increased postprandial triglyceride or 
chylomicron concentration suggesting that the basal rate of chylomicron production and 
lipolysis is sufficient to avoid exaggerated postprandial lipaemia following low dose of fat 
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consumption (Dubois et al., 1998). Triglyceride clearance capacity was able to 
proportionally balance the fat assembled following fat load of 30 – 50 g fat. However when 
given a very high dose of fat load (80 g or more), exaggerated postprandial 
hypertriglyceridaemia ensues but not in dose-dependent pattern (Denis Lairon, 2008). 
Chylomicron production in the enterocytes has the ability to accommodate a wide 
range of amounts of dietary fat by increased particle size or an increase in particle number 
secreted, or both. Consumption of a low fat dose (<14 g) in healthy males resulted in no 
significant increase in postprandial apo B-48 response (Anthony P. James & John C. Mamo, 
2012). It seems that at low dose fat loading, the chylomicrons may respond by increasing 
their particle size instead of their particle number and the fat load is accommodated by the 
basal rate of chylomicron secretion and/or efficient lipolysis and clearance (Hayashi et al., 
1990). In contrast, following consumption of a moderate fat dose (>19 g) increased 
postprandial chylomicron concentration ensued. This increased postprandial 
chylomicronaemia may result from an increased chylomicron secretion or delayed lipolysis 
and clearance. 
Although dietary lipids are primarily packaged into chylomicron particles in the 
postprandial state, recent evidence suggests that a portion of these are stored as cytosolic 
lipid droplets within the enterocyte. These may represent a source of triglyceride for 
chylomicron production during the interprandial phase (Beilstein, Carrière, Leturque, & 
Demignot, 2016).  
A number of studies have compared the effect of different dietary fatty acid 
composition on postprandial triglyceride, apo B-48 and/or chylomicron responses. The fatty 
acid chain length and presence of double bonds affects their metabolic pathway and thus 
the extent of postprandial triglyceride or chylomicron response. Short and medium chain 
triglycerides are completely hydrolysed to fatty acids and glycerol by pancreatic lipase. They 
are mainly absorbed as free fatty acids and only a very small portion as mono-
diacylglycerols (Bach & Babayan, 1982). Fatty acids with shorter chain length (less than 12-
14 carbons) are not good substrates for esterification due to the absence of specific 
medium-chain acyl-CoA synthase (Frayn, 2009) and they are not easily bound to fatty acid 
binding protein (Bach & Babayan, 1982). Therefore they are rapidly absorbed into 
circulation via the hepatic portal vein as NEFA bound to albumin and are transported to the 
liver to be oxidised. Thus fat challenges using meals rich in short fatty acid or medium chain 
fatty acid generally results in a lower postprandial triglyceride response (Mekki, 
Charbonnier, Borel, Leonardi, & et al., 2002). A kinetic study showed no significant change 
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in apo B-48 pool size and no effect on TRL apo B-48 production rate and clearance following 
coconut based MCT oil consumption (Tremblay et al., 2014).  
 The effect of long chain fatty acids (saturated, monounsaturated and 
polyunsaturated fatty acid) on the postprandial lipid response is much more complex. 
There are several proposed mechanisms involved in modulation of postprandial lipid 
response by different types of fatty acids. Animal and in vitro studies have reported that 
the rate of absorption and preference for incorporation of dietary fatty acids into 
triglyceride or other lipids in enterocytes modulates the chylomicron postprandial 
response. Long chain SFA are poorly absorbed and therefore will influence triglyceride 
availability for the chylomicron assembly (Kalogeris & Story, 1992). Thus it is expected that 
they would be retained in the enterocytes longer and/or released as part of smaller sized 
chylomicron particles. In addition to chain length, gastrointestinal lipid handling is also 
influenced by the degree of saturation. Stearic acid is substantially less absorbed than 
palmitic acid, oleic acid or linoleic acid (A. E. Jones, Stolinski, Smith, Murphy, & Wootton, 
1999) (P. J. H. Jones, Pencharz, & Clandinin, 1985). The differences in absorption could be 
attributed by difference in affinity to bind fatty acid binding proteins or difference in lipid 
partitioning in the enterocytes. An in vitro study using the Caco-2 intestinal cell line 
demonstrated that cells incubated with palmitic acid secreted more dense lipoproteins 
than those incubated with linoleic acid (Van Greevenbroek, Voorhout, Erkelens, Van Meer, 
& De Bruin, 1995). A greater proportion of linoleic acid was incorporated into triglyceride 
than palmitic acid. However inconsistent findings were observed in human studies. 
Compared to palmitate and oleate, linoleate is incorporated more into phospholipids and 
cholesteryl ester (Hodson, McQuaid, Karpe, Frayn, & Fielding, 2009). Among SFA, myristate 
is preferentially partitioned into triglyceride (>95%) whereas a greater portion of palmitate 
(18%) and stearate (33%) are partitioned into phospholipids (Hughes et al., 1996).  
Dietary fatty acid composition has also been recognised to affect chylomicron 
metabolism through modulation of their lipolytic rate and clearance. Chylomicrons 
containing PUFA are converted to chylomicron remnants more rapidly than those 
containing SFA or MUFA. This could be due to different lipolytic rate by LPL and different 
preferential hepatic uptake by HL with the higher preference for PUFA-enriched 
chylomicrons (Kathleen M. Botham, Avella, Cantafora, & Bravo, 1997; Bravo et al., 1995; 
Rahman, Avella, & Botham, 2000). Animal and in-vitro studies showed a greater LPL 
hydrolysis of short chain unsaturated monoacyl glycerol and triglyceride (Groot, de Boer, 
Haddeman, Houtsmuller, & Hülsmann, 1988; Hulsmann, Oerlemans, & Jansen, 1980). The 
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mechanism of increased adipose LPL activity following PUFA challenge could be through 
activation of PPAR γ induced by linoleic acid and arachidonic acid serving as PPAR γ agonists 
(Oyekan, 2011; Schoonjans et al., 1996). In humans, n-3 PUFA reduces postprandial 
triglyceride and chylomicron response by directly increasing LPL activity during fed state 
and enhanced chylomicron clearance partly through reducing VLDL secretion (Park & Harris, 
2003). The findings of increased LPL activity are inconsistent for MUFA (Bergouignan, 
Momken, Schoeller, Simon, & Blanc, 2009). Dietary n-3 and n-6 PUFA could also modulate 
uptake via upregulation of hepatic LDLR expression (Spady & Woollett, 1990). Dietary fats 
have also been found to modify apolipoprotein composition and thus may affect fatty acid 
handling. Meals containing SFA induce a greater amount of apo E and apo C-III in 
triglyceride-rich lipoproteins than meals rich in unsaturated fatty acids (K. G. Jackson, 
Wolstencroft, Bateman, Yaqoob, & Williams, 2005).  
The ability of enterocytes to absorb a wide range quantity of dietary fats by shifting 
the size of chylomicron released from small/VLDL-like in the interprandial state to large 
chylomicrons is a result of metabolic adaptation of the enterocyte to the lipid influx from 
the diet (Buttet et al., 2014). When challenged with a fatty meal, chylomicrons tend to 
increase their size instead of increasing their particle numbers indicating the presence of 
this lipid driven metabolic adaptation (Cartwright & Higgins, 1999; Karpe, Olivecrona, 
Hamsten, & Hultin, 1997). In situ, an isolated segment of jejenum from mice fed a high fat 
diet (40% weight/weight) for 6 weeks was able to absorb a greater amount of fatty acids 
and induce higher mitotic index and mRNA expression of genes involved in lipid uptake 
(FATP4, FAT/CD-36), intracellular trafficking (intestinal and liver fatty acid binding proteins/ 
I-FABP and L-FABP) and lipoprotein synthesis (MTP, apo A-IV) (Petit et al., 2007). LPL 
regulators (apo C-II and apo C-III) were also modulated to maintain efficient triglyceride 
clearance.  
Consumption of isocaloric diets rich in SFA, n-6 PUFA and n-3 PUFA for 25 days in 
normolipidemic subjects showed that the postprandial chylomicron response to a single 
oral fat challenge was greater in SFA diet followed by n-6 PUFA and n-3 PUFA (M. S. 
Weintraub, Zechner, Brown, Eisenberg, & Breslow, 1988). In that study, chylomicrons 
containing n-6 PUFA and n-3 PUFA produced during each acute postprandial test were 
hydrolysed faster than the SFA-containing chylomicrons whereas no effect of chronic diets 
was observed on lipolysis. It is suggested that chronic diets are more likely to affect the 
catabolic machinery. Recently, a 12-week supplementation with n-3 fatty acid ethyl esters 
(46% eicosapentaenoic acid and 38% doxosahexaenoic acid) in obese individuals on 
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hypocaloric diet results in a decreased baseline and postprandial triglyceride and apo B-48 
response (A. T. Y. Wong, Chan, Barrett, Adams, & Watts, 2014). The n-3 fatty acid ethyl 
ester supplementation reduces basal apo B-48 secretion rate but not during the 
postprandial state.   
In summary many factors affect chylomicron metabolism. Circulating NEFA 
modulates chylomicron production whereas insulin reduces chylomicron production and 
maintains efficient chylomicron hydrolysis and uptake. Dietary fats affect chylomicron 
metabolism at almost every stage (absorption, intestinal lipid partitioning, lipolysis and 
removal). 
 
1.4 Chylomicron and hepatic lipoprotein interactions in postabsorptive and postprandial 
state 
To maintain a balanced steady state of lipid homeostasis between the postabsorptive and 
postprandial states, intestinal and hepatic derived TRL exhibit many dynamic and well-
coordinated interactions. In the postabsorptive state, lipid absorption in the intestine 
practically ceases however the production and release of lipid-poor apo B-48 and hepatic 
derived lipoproteins continue (C. Xiao et al., 2011). The presence of chylomicrons in the 
circulation during the fasting state has been reported previously (Campos, Khoo, & Sacks, 
2005; A. P. James & J. C. Mamo, 2012; Karpe, Bell, Bjorkegren, & Hamsten, 1995; Karpe & 
Hamsten, 1994; Mamo, Smith et al., 1998; Schaefer, Jenkins, & Bryan Brewer Jr, 1978). It is 
suggested that the source of lipid in the intestine is derived from: 1) NEFA and glycerol 
imported from the circulation; 2) NEFA generated from de novo lipogenesis in enterocytes 
(Federico et al., 2006; Haidari et al., 2002); and 3) release of triglyceride from cytosolic lipid 
droplets in enterocytes (Beilstein et al., 2016; Shojaee-Moradie, Ma, Lou, Hovorka, & 
Umpleby, 2013; C. Xiao et al., 2011).  
During fasting, endogenous triglyceride production maintains the continuity of 
substrate supply for extrahepatic tissues. Approximately 20 – 30 g/day endogenous 
triglyceride is produced through VLDL in normolipidemic males (M. Adiels et al., 2006; 
Cohn, Patterson, Uffelman, Davignon, & Steiner, 2004), a much lower concentration than is 
typically transported from the intestine (around 100 g/day with almost complete 
absorption) in postprandial state (Gades & Stern, 2005; C. Xiao et al., 2011). The source of 
lipid in VLDL during the fasting state is mostly derived from the circulating NEFA released 
from adipose tissue lipolysis (70 – 80%) (Barrows & Parks, 2006). 
18 
 
 Food ingestion initiates the transition from fasted to fed states. The chylomicron 
response to a meal starts even before ingested. Tasting, but not swallowing, the meal has 
been reported to trigger an increased release of chylomicrons suggesting a taste-gut-brain 
axis involvement in preparing the digestive systems including enterocyte synthesis and the 
capacity of chylomicrons for the incoming lipid load (Buttet et al., 2014; Mattes, 2009). 
Following dietary absorption, chylomicron secretion capacity increases preferentially 
through lipid enrichment and enlargement of their particle size rather than increasing the 
particle number (Cohn, McNamara, Cohn, Ordovas, & Schaefer, 1988). Approximately 82% 
of the increased postprandial triglyceride concentration is contributed by the apo B-48 TRL-
derived triglyceride (Cohn et al., 1993).  Despite this substantial contribution, the increase 
in apo B lipoprotein postprandially is mainly contributed by apo B-100 and not apo B-48 
lipoproteins due to competition for hydrolisis in which apo B-48 lipoproteins are more 
preferred (Brunzell, Hazzard, Porte Jr, & Bierman, 1973; Karpe et al., 1995). The lipid-rich 
chylomicrons in the circulation are hydrolysed by insulin-stimulated LPL and eventually 
become enriched in cholesteryl ester. The majority of the triglyceride content in 
chylomicrons is taken up by extrahepatic tissues expressing LPL. During hydrolysis, a 
portion of NEFA escapes from cellular uptake and enters the plasma pool. This NEFA spill 
over may be utilised for the synthesis of chylomicron and VLDL or stored as lipid droplets in 
the enterocyte and liver respectively.  
The interaction between chylomicrons and hepatic VLDL in maintaining lipid 
homeostasis in both postabsorptive and postprandial states is also mediated by gut 
hormones. Immediately after meal ingestion, L and K cells located in the distal intestine are 
stimulated resulting in GLP-1 secretion. GLP-1 then induces β cells in pancreas to secrete 
insulin. In the postprandial state, the increased insulin concentration down-regulates 
adipose tissue lipolysis, and NEFA flux to the liver and intestine. Postprandial 
hyperinsulinemia may also suppress the production of nascent chylomicron and VLDL 
particles in order to minimise competition for lipolysis and removal between chylomicron 
and VLDL particles (C. Xiao et al., 2011).  
In summary, to ensure the continuity of lipid transport in the circulation in the 
postabsorptive, postprandial and the transition between these states, the interaction 
between chylomicrons and hepatic VLDL involves a range of signals including nutrient, 
neural and hormonal. These signals implicate chylomicron and hepatic VLDL metabolism at 
various stages: lipoprotein assembly, transport, storage, redistribution and clearance. In 
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conditions where accumulation of chylomicron remnants occurs, this efficient interaction is 
disrupted resulting in a greater exposure of cholesterol rich remnants to the vascular wall.   
 
1.5 Cholesterol-rich chylomicrons 
The increase in circulating lipoprotein particle number in the postprandial state is mostly 
due to an increase in apo B-100 containing lipoproteins with apo B-48 containing 
lipoproteins only contributing 20% of the increased particle number (Karpe et al., 1995; 
Schneeman, Kotite, Todd, & Havel, 1993). Despite there being a lower number of 
chylomicron particles in circulation, each chylomicron remnant has been reported to 
contain 63,900 cholesterol molecules whereas one LDL particle contains only 1,771 
cholesterol molecules, a 40 times more than LDL which may explain their atherogenicity (C. 
J. Fielding, 1992). 
 The source of cholesterol in chylomicrons can be from diet and/or from 
endogenous lipid exchange with cholesterol-rich lipoproteins (HDL and LDL). Both 
chylomicron and HDL lipoproteins play an important role in the transport of dietary 
cholesterol from the intestine (Hussain, 2014; Iqbal & Hussain, 2005). Cholesterol esters are 
mostly carried by chylomicrons and this process is mediated by MTP whereas free 
cholesterol is carried by HDL via ABCA1. The contribution of cholesterol carrying capacity is 
greater in chylomicrons than in HDL apo A-1 lipoproteins. Intestinal MTP-ablated mice 
exhibit reduced cholesterol absorption by around 92% and enterocytes secretion by 70% 
(Iqbal, Parks, & Hussain, 2013). Ablation of intestinal ABCA1 in mice resulted in 28% and 
30% decrease in cholesterol absorption and secretion respectively. Combined deficiency of 
MTP and ABCA1 decreased cholesterol secretion by 80%. 
 The other source of cholesterol in chylomicrons is from endogenous lipid exchange 
in reverse cholesterol transport. Reverse cholesterol transport is the movement of 
cholesterol from peripheral cells to the liver via plasma compartment (C J Fielding & 
Fielding, 1995; Frayn, 2009). Cholesterol from peripheral cells is transported to the liver by 
apo A-I particles via ABCA1 or by more mature spherical HDL particles via ABCG1. For 
efficient cholesterol uptake, within HDL particle free cholesterol is esterified into 
cholesteryl ester by LCAT clearing more space for additional free cholesterol uptake on the 
HDL surface (Annema & Tietge, 2012). In the plasma compartment, this cholesterol is 
transported in a reverse pathway heading back to the liver. In humans and a number of 
species, CETP, a hydrophobic glycoprotein, provides a shunt between the forward and the 
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reverse cholesterol transport pathways by facilitating neutral lipid (cholesteryl ester, 
triglyceride, retinyl ester and a small portion of phospholipid) transfer between triglyceride-
rich (chylomicron and hepatic derived) lipoproteins and cholesterol-rich lipoproteins (LDL 
and HDL particles) (Tall, 1993). CETP can promote net transfer of cholesteryl ester made by 
LCAT with or without an equimolar exchange of triglyceride. In individuals with normal 
CETP activity, the major route of cholesterol uptake by the liver is through chylomicron 
remnants, hepatic VLDL remnants and LDL (Tall, 1993). This lipid transfer has been 
suggested to maintain intact HDL homeostasis by balancing the augmentation of HDL mass 
(driven by LPL and LCAT) with a reduction in HDL mass by diverting their cholesteryl ester 
content to triglyceride-rich lipoproteins facilitated by CETP and HL. In contrast, in conditions 
where CETP activity increased (such as in high fat consumption and in insulin resistance), 
the transfer rate of cholesteryl ester from HDL to TRL is augmented resulting in a high influx 
of cholesterol to the liver. The excessive deposition of cholesterol in the liver eventually 
down-regulates LDLR expression. As a result, cholesterol-rich remnants will build up in the 
circulation. 
 
1.6 The role of chylomicrons in atherogenesis 
The theory that atherosclerosis is a postprandial phenomenon has attracted a lot of 
attention since the finding of cholesterol-rich chylomicron remnants accumulated in tunica 
intima of animal models (D. B. P. D. Zilversmit, 1979). Since then numerous studies have 
attempted to elucidate the potential mechanism for this accumulation. Atherosclerosis 
arises from the accumulation of fatty deposits in the arterial wall. According to the 
Response-to-Retention model of atherogenesis, the initial stage involves the retention of 
apo B lipoproteins (chylomicron remnants, VLDL remnants, and LDL) on subendothelial 
extracellular matrix (K. J. Williams & Tabas, 1995; K. J. Williams & Tabas, 2005). The 
retained lipoproteins undergo modification (i.e. aggregation, oxidation) and induce a 
maladaptive inflammatory response involving: activation of endothelial cells, monocytes 
entering subendothelial tissue and endocytosis of the retained lipoproteins by monocyte-
derived macrophages resulting in the formation of cholesterol-laden foam cells (Tabas, 






1.6.1 Subendothelial accumulation of atherogenic remnants 
The entry of lipoproteins into subendothelial tissue depends on the concentration of 
lipoproteins accumulated in the circulation and the lipoprotein properties (size, charge and 
endothelial permeability/ability to bind to proteoglycan) (Tabas et al., 2007). In the 
circulation, lipoproteins dynamically flux into and out of the arterial wall by transcytosis, a 
transport system using a specialised clathrin-coated plasmalemmal vesicles (M. Simionescu 
& Simionescu, 1991). The size of this vesicle is 100 nm in diameter and thus can only 
transport lipoproteins and macromolecules less than 70 nm in diameter. Therefore large 
lipoproteins such as chylomicrons and hepatic VLDL cannot cross the endothelium but their 
remnants can (D. B. Zilversmit, 1995). 
Chylomicron remnants can penetrate the artery walls as effectively as LDL. The rate 
of intimal clearance and fractional loss of remnant sized lipoproteins (Sf 12 – 60) was 
observed to be similar to that of LDL sized lipoproteins in an in vivo study of subjects 
undergoing elective carotid endarterectomy (Shaikh et al., 1991). This finding suggests that 
remnants may contribute to the accumulation of lipid in subendothelial matrix. 
It is estimated that approximately 2500 transport vesicles leave the endothelial 
plasma membrane per minute (G. M. Dallinga-Thie, Kroon, Borén, & Chapman, 2016). Thus 
the selectivity of lipoproteins to enter and be retained within subendothelial tissue 
depends on the extent which they interact with the subendothelial matrix. An important 
component of the subendothelial matrix related to lipoprotein retention is proteoglycan. It 
has been suggested that the retention of lipoproteins is due to the interaction between 
positively charged apo B lipoproteins and negatively charged sulphate groups of 
proteoglycan sugar (Tabas et al., 2007).  Apo B-48 containing lipoproteins bind to 
proteoglycan at site B-Ib of apo B-48 (Flood et al., 2002). Evidence supporting the selectivity 
of chylomicrons retained within subendothelial tissue also comes from a study using an 
atherosclerosis-prone animal model showed a greater arterial retention of apo B-48 
containing lipoprotein than apo B-100 containing lipoproteins (Proctor, Vine, & Mamo, 
2002). The causal mechanism between lipoproteins, proteoglycans and early atherogenesis 
has been demonstrated in an animal study showing that mice expressing proteoglycan-
binding-defective LDL develop less atherosclerotic lesions than the wild-type mice LDL 
(Skalen et al., 2002). 
 An additional factor that may promote lipoprotein retention is the presence of LPL 
in the arterial wall. LPL can promote lipoprotein retention by its non-enzymatic function in 
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bridging lipoprotein-matrix (Proctor et al., 2002).  Large TRLs (apo B-48 and apo B-100 
containing TRLs) are hydrolysed by LPL and their size would shrink reaching to the size 
where they are able to penetrate the subendothelial tissue. This explains why patients with 
LPL deficiency do not develop atherosclerosis (Mamo, 1995). LPL may also be an anti-
atherogenic molecule through LPL-mediated lipolysis and lipoprotein removal from the 
circulation. 
 
1.6.2 Chylomicron remnants, monocyte/macrophage activation and foam cell 
formation 
Once remnants in the subendothelial tissue, they interact with monocytes resulting in 
intracellular lipid accumulation of monocytes and induction of inflammatory response 
which would activate monocytes. Monocytes can be activated through accumulation of 
cytosolic lipid droplets (Bentley et al., 2011), upregulation of apo B-48 receptor mRNA 
expression (Bermudez et al., 2012; Varela et al., 2011) and LRP1 (Gower et al., 2011), 
increase expression of leukocyte activation markers (CD11b) (Alipour et al., 2008), 
upregulation of a number of markers related to monocyte adhesion (Gower et al., 2011; 
Kawakami, Tanaka, Nakajima, Shimokado, & Yoshida, 2002), increased production of 
reactive oxygen species (Bentley et al., 2011) and modulation of migratory and chemotaxis 
markers (IL-8, MCP1) (Bentley et al., 2011). These mechanisms will result in the adherence 
of monocytes to the endothelium.  
The presence of chylomicron remnants in the subendothelial tissue may induce a 
substantial increase in cytoplasmic lipid droplets in animal and human macrophage cell line 
studies (Batt et al., 2004; Fujioka, Cooper, & Fong, 1998; Napolitano, Rivabene, Avella, 
Botham, & Bravo, 2001; Yu & Mamo, 2000). Chylomicron remnants are also able to interact 
directly with macrophages to trigger foam cell formation (Fujioka et al., 1998; Mamo, 1995; 
Proctor & Mamo, 1996; Proctor et al., 2002). Accumulation of lipid engorged macrophage 
foam cells forms fatty streak, the hallmark of atherosclerosis. Several mechanism of uptake 
chylomicron remnants by macrophages have been reported: receptor-mediated LDLR and 
LRP1 apo E-dependent (Bejta et al., 2007), apo B48R apo B-dependent (M. L. Brown et al., 
2000),  scavenger receptor CD36 (Bejta et al., 2007), non-receptor mediated pathway via 
LPL (K. M. Botham & Wheeler-Jones, 2013; Palmer et al., 2005) and phagocytosis (Bejta et 
al., 2007; Elsegood & Mamo, 2006; Mamo, Elsegood, Gennat, & Yu, 1996). Indeed the 
presence of chylomicron apo B-48 in atherosclerotic tissue together with apo B-100 in 
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human atherosclerotic plaque has been reported (Nakano et al., 2008; Pal, Semorine, 
Watts, & Mamo, 2003). 
 
1.7 Chylomicron and postprandial lipaemia 
In subjects consuming three or four meals and snacks per day, triglyceride concentrations 
increase by 70% over the course of 24-hours with triglyceride reaching the fasting level only 
in the early morning (3:00 – 6:00 AM) (C. M. Williams, 1997). The repeated consumption of 
lipid-rich meals throughout the day and the fact that their complete metabolism may take 
up to 8-10 hours (Frayn, 2009) indicates that human body is exposed to circulating dietary 
lipids throughout the day.  
 
1.7.1 Postprandial lipaemia: Definition and diagnosis 
Postprandial lipaemia is a normal physiological condition where TRL and remnants are 
increased postprandially. During the postprandial state, the main change in lipid 
parameters in the blood is hypertriglyceridaemia. Postprandial hyperglycemia may occur, 
however this happens in the earlier postprandial period (Kolovou, Anagnostopoulou, 
Daskalopoulou, Mikhailidis, & Cokkinos, 2005). In normal postprandial lipaemia, the 
increase in triglyceride and TRL concentration are transitory and generally will last from 6 – 
8 hours after fatty meal ingestion (D. C. Chan, Pang, Romic, & Watts, 2013). It is suggested 
that the mechanism of postprandial hypertriglyceridaemia is a result of competition 
between intestinal and hepatically derived TRL (chylomicrons and hepatic VLDL) for lipolysis 
and clearance.  
The importance of measuring lipid profile postprandially emerges after prospective 
studies have shown that nonfasting triglyceride concentration predicts the cardiovascular 
events (myocardial infarction, ischemic heart disease) (Bansal et al., 2007; B. G. 
Nordestgaard, Benn, Schnohr, & Tybjærg-Hansen, 2007). Epidemiological studies have 
shown that the risk of a cardiovascular event increase when the non-fasting triglyceride 
concentration is 165 mg/dL in Japan (Teramoto et al., 2013) and 175 mg/dL in Europe 
(Børge G. Nordestgaard et al., 2016). Bansal et al (2007) reported that higher nonfasting 
triglyceride concentration was associated with an increased risk of future cardiovascular 
events (nonfatal myocardial infarctions, ischemic strokes, coronary vascularisation, 
cardiovascular mortality) (Bansal et al., 2007). This association was independent of the 
baseline cardiac risk factors, other lipid levels (total and HDL cholesterol) and insulin 
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resistance. In contrast, the association between fasting triglyceride concentration and 
cardiovascular event weakened after adjustment for these factors. Nonfasting triglyceride 
concentration collected 2 – 4 hours after the last meal showed the strongest association 
with the occurrence of cardiovascular events. Similarly, Nordestgaard et al (2007) also 
reported that increased nonfasting triglyceride was associated with increased risk of 
myocardial infarction, ischemic heart disease and mortality (B. G. Nordestgaard et al., 
2007). They also demonstrated that with increased nonfasting triglyceride, remnant 
cholesterol concentration also increased. In response to normal food intake, the change of 
lipid, lipoproteins and apolipoprotein profiles were minimal, therefore the use nonfasting 
triglyceride level to predict cardiovascular disease risk would be more preferable since it 
simplifies the clinical care of the patients (Langsted, Freiberg, & Nordestgaard, 2008). 
Currently there is still no established method for diagnosing impaired postprandial 
lipaemia. To assess the TRL postprandial response, standard methods measuring the 
response of plasma triglyceride, retinyl esters, remnant-like particles or apo B-48 after 
ingesting an oral fat load following an overnight fast can be applied (D. C. Chan et al., 2013). 
Postprandial responses are generally analysed as the total area under the curve (AUC), 
indicating the total lipid response to a fat load, and the incremental AUC (IAUC), 
representing the change in lipid response beyond baseline levels. Apo B-48 is considered as 
the most suitable marker as it is a non-exchangeable marker for the quantity of circulating 
chylomicron particles/remnants (Smith, Watts, Dane-Stewart, & Mamo, 1999). It is 
recommended that the lipid content of the test meal should be between 40 – 60 g, an 
amount that can stimulate lipid metabolism without overloading the system, and include 
protein and carbohydrate (minimal 50 – 100 g) to provoke adequate insulin response (D. 
Lairon, Lopez-Miranda, & Williams, 2007).  
 
1.7.2 Exaggerated postprandial lipaemia 
In postprandial hypertriglyceridaemia, the magnitude and the duration of the TRL response 
is exaggerated resulting in accumulation of TRL and their remnants in the circulation. It has 
been suggested that the clearance capacity of remnants is the main determinant of the 
accumulation of chylomicrons and chylomicron remnants and the magnitude of 
postprandial lipaemia (Martin Adiels et al., 2012). A decreased capacity of clearance 
pathways could be due to decreased hepatic receptor activity, defect on the ligand of the 
receptor (i.e. apo A-V, apo E, apo C-III) and impaired LPL activity (D. C. Chan et al., 2013). 
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The greater the magnitude and the duration of postprandial lipaemia, the greater the 
exposure of vascular wall to cholesterol-rich remnants. 
 
1.7.2.1 Obesity  and insulin resistance 
Previous studies have demonstrated that overweight/obese subjects had raised fasting 
concentration of chylomicron particles (Couillard et al., 2002; Annette T. Y. Wong, Chan, 
Pang, Watts, & Barrett, 2014) suggesting impaired TRL metabolism. A recent prospective 
cohort study in children, whom at least one of the parents was classified as obese or large 
waist, demonstrated that over 2-year period, greater changes in central adipocity was 
associated with apo B-48 compared to the classic lipid markers (Wilke et al., 2016). For 
every increase of 1 kg/m2 in central obesity, there were approximately 14 times increase in 
apo B-48 concentration in children with lower baseline central fat mass index compared to 
those with higher baseline.  
Increased adiposity is associated with an increased influx of NEFA to the liver which 
will stimulate hepatic VLDL production and gluconeogenesis. An increased in-flux of NEFA 
entering the liver also impairs the hepatic extraction of insulin leading to hepatic insulin 
resistance. Insulin resistance increases de novo lipogenesis in the liver and the amount of 
fatty acids and triglyceride entering the liver due to a reduction in its normal antilipolytic 
effect in adipose and extra-hepatic tissues (Pavlic et al., 2010). LDLR expression is also 
altered resulting in impaired catabolism of apo B containing lipoproteins (D. C. Chan et al., 
2013). Insulin resistance also affects intestinal TRL metabolism via overproduction of apo B-
48 lipoprotein (Duez et al., 2006). Results from a kinetic study in obese individuals has 
revealed that exaggerated postprandial lipaemia in visceral obesity is associated with 
overproduction and disrupted catabolism of apo B-48 containing lipoproteins (Annette T. Y. 
Wong et al., 2014).  
 
1.7.2.2 Metabolic syndrome 
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities characterised by 
dysglycemia, raised blood pressure, elevated triglyceride concentration, low high density 
lipoprotein (HDL) cholesterol level and obesity (central adiposity) (Alberti et al., 2009). It 
has been reported that individuals with MetS exhibit an exaggerated postprandial 
triglyceride response (Kolovou, Anagnostopoulou, Pavlidis et al., 2005). The magnitude of 
the postprandial triglyceride response has been found to increase with increasing number 
26 
 
of MetS components that an individual possesses  (K. G. Jackson et al., 2012). Men who had 
less than 3 components of MetS exhibited lower incremental triglyceride response to a 
sequential meal challenge than those with 3 or more MetS components. 
The pathophysiology of MetS is largely attributed to insulin resistance (Eckel, 
Grundy, & Zimmet, 2005). Increased supply of hepatic lipid substrate and delayed clearance 
of TRL and remnants has been suggested as the mechanism of MetS (Dick C. Chan, Barrett, 
& Watts, 2004). The production rate of both chylomicron and VLDL triglyceride increased 
(Annette T. Y. Wong et al., 2014). Lipolysis and clearance of TRL or remnants were delayed, 
which might be due to decreased LPL activity, hepatic remnant receptor (LDLR) activity and 
the synthesis of HSPG mediated by insulin resistance (D. C. Chan, Watts, Barrett, Mamo, & 
Redgrave, 2002; D. C. Chan, Watts, Redgrave, Mori, & Barrett, 2002; Mamo et al., 2001). 
MetS is also associated with the increased synthesis of apo C-III possibly due to decreased 
expression of hepatic PPAR α has also associated with MetS (Shachter, 2001). Apo C-III 
inhibits lipolysis and hepatic clearance. 
 
1.8 Evidence to date: Metabolic determinants of chylomicron accumulation 
1.8.1 Introduction 
According to the Response-to-Retention theory of atherogenesis, retention of remnants 
(chylomicrons and hepatic VLDL) in subendothelial tissue serves as the initiator for 
atherogenesis (K. J. Williams & Tabas, 1995; K. J. Williams & Tabas, 2005). Evidence has 
shown that fasting serum apolipoprotein B-48 concentration, a measure of chylomicron 
particle number, is significantly associated with the existence of atherosclerosis and 
coronary artery disease (Alipour et al., 2012; Masuda et al., 2012). Previous studies have 
demonstrated that overweight / obese subjects exhibiting impaired lipid metabolism also 
had raised fasting concentration of chylomicron particles (Couillard et al., 2002; Annette T. 
Y. Wong et al., 2014). Higher fasting chylomicron concentration was also found in subjects 
with MetS (Kinoshita et al., 2009). Those metabolic phenotypes are at risk of CVD indicating 
the possibility of some commonalities in terms of metabolic defects affecting both 
chylomicron metabolism and the other parameters. In the next section we will discuss 
evidence to date of studies investigating the association between chylomicron and other 





1.8.2 Metabolic determinants 
A limited number of studies have investigated the association of apo B-48 concentration 
with other lipid or metabolic parameters (Table 1.1) (Hanada et al., 2012; Kinoshita et al., 
2009; Sakai et al., 2003; Sato et al., 2009). In these studies the concentration of 
chylomicron particles, as measured by apo B-48, was strongly associated with triglyceride 
concentration. In the fasting state, plasma triglyceride concentration is mainly contributed 
by triglyceride carried by VLDL and their remnants. It is interesting that despite apo B-48 
being much lower in concentration than apo B-100 in the fasting state, apo B-48 was still 
significantly associated with triglyceride suggesting a common metabolic defect leading to 
accumulation of these triglyceride-rich lipoproteins.  
 Apo B-48 level in normolipidaemic and hyperlipidaemic subjects has been elegantly 
reported by Sakai et al. (2003). They investigated the fasting concentration of apo B-48 in 
normolipidemic (n=335) and hyperlipidemic Japanese (n=253) (Sakai et al., 2003). They 
reported that apo B-48 concentration strongly correlated with triglyceride concentration 
(r=0.45) but not with total cholesterol. The distribution of fasting apo B-48 concentration in 
the nomolipidaemic subjects in this study was not normally distributed suggesting that 
among these subjects, there was a group of subjects exhibiting hyperchylomicronaemia 
despite having normal lipid levels. The increased fasting apo B-48 indicates impaired 
removal of chylomicron/chylomicron remnants from the circulation (Sakai et al., 2003). In 
the hyperlipidaemic subjects, the distribution of apo B-48 varied widely with a very high 
concentration of apo B-48 in subjects with type I (LPL deficiency), III (familial 
dysbetalipoproteinemia) and V hyperlipidaemia (total cholesterol concentration ≥220 
mg/dl and triglyceride concentration ≥500 mg/dl). Despite this subjects with type I, III and V 
hyperlipidaemia exhibited increased fasting triglyceride, the atherogenicity risk differed. 
Type III hyperlipidaemia is more susceptible to develop atherosclerosis due to the increased 
number of circulating small particles whereas type I and V hyperlipidaemia exhibited 
increased number of apo B-48-containing lipoprotein and triglyceride enrichment in 
chylomicron particles.  
In addition to triglyceride, chylomicrons also hold a crucial role in transporting 
dietary cholesterol together with HDL pathway and the involvement of chylomicrons in 
reverse cholesterol transport. HDL cholesterol and LDL cholesterol are generally accepted 
as markers for higher CVD risk. However, findings from previous studies consistently 
showed weak or no association between apo B-48 with cholesterol profile (total 
cholesterol, LDL cholesterol and HDL cholesterol). Kinoshita et al (2009) reported that the 
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association between apo B-48 level and cholesterol profile was weak (r between apo B-48-
total cholesterol 0.24 in men and 0.2 in women and r between apo B-48-HDL cholesterol -
0.18 in men and -0.15 in women) (Kinoshita et al., 2009). Sato et al (2009) found no 
significant association between apo B-48 and total cholesterol, LDL and HDL cholesterol 
concentration. Instead they reported a strong correlation between apo B-48 and 
triglyceride concentration (r=0.791), RLP-triglyceride (r=0.745), RLP-cholesterol (r=0.768) 
and remnant lipoprotein cholesterol (r=0.811). (Sato et al., 2009).  
Based on the findings of the above-mentioned studies and the atherogenicity 
evidence of chylomicrons, the utilisation of triglyceride and HDL cholesterol concentration 
as surrogate markers for a higher risk of CVD may need to be revisited. HDL cholesterol 
does not represent cholesterol content in the chylomicron remnants and hepatic derived 
remnants. Instead those cholesterol portions are captured when non-HDL cholesterol or 
remnant cholesterol concentration is measured. To the best of our knowledge, association 
between apo B-48 and non-HDL cholesterol or remnant cholesterol concentration has not 
been explored yet. Similarly, despite having high triglyceride concentration, the atherogenic 
risk of different type of hyperlipidaemia differs. This underscores the importance to 
evaluate the utilisation of increased triglyceride concentration as a marker for 
atherogenicity. 
The association between apo B-48 concentration with other parameters has been 
reported. Kinoshita et al (2009) demonstrated that HOMA-IR level and BMI significantly 
associated with apo B-48 concentration (Kinoshita et al., 2009). In contrast Hanada et al 
(2012) found no significant contribution of BMI to the variability of apo B-48 concentration 
(Hanada et al., 2012). Considering that these studies were conducted in the Japanese 
population, therefore it is important to also demonstrate whether this observation holds in 
other populations. Ethnic variability implicates the body fat percentage and muscularity and 
thus may affect lipid utilisation leading to modification of risk of metabolic disease 
(Deurenberg, Deurenberg-Yap, & Guricci, 2002; Dulloo, Jacquet, Solinas, Montani, & Schutz, 







1.9 Evidence to date: The effect of dietary fatty acid composition on chylomicron size 
distribution and postprandial lipemia 
1.9.1 Introduction 
Atherosclerosis is a multifactorial disease. It is widely accepted that in addition to genetics 
and environment, dietary composition plays an important role in particular the quantity 
and type of dietary fat present. Type of dietary fatty acid composition has been recognised 
to modulate TRL response through their effect on lipid partitioning, chylomicron production 
and removal, and accessory factors (i.e. insulin). After being absorbed in the enterocytes 
and released into the circulation, nascent chylomicrons carrying dietary triglyceride and 
cholesterol are hydrolysed by LPL in extrahepatic capillary beds. This process removes a 
portion of their lipid content resulting in a reduction in their particle size. In the circulation, 
chylomicrons also acquired other apolipoproteins including apo E to prepare them for 
removal from the circulation by the liver. Smaller, partially hydrolysed remnants have been 
suggested to be more atherogenic than the larger TRL (Evans et al., 1993; Ji et al., 1993; 
Krauss, 1998). One technique to detect and quantify small sized remnants is by separating 
remnant lipoproteins according to their density (Cohn et al., 1999). The next sections will 
discuss methods to assess chylomicron size distribution and evidence to date from human 
studies investigating the effect of dietary fats on lipoprotein fraction response in 
postprandial lipaemia.     
 
1.9.2 Methods to assess chylomicron size distribution 
In previous studies, investigation on chylomicron during postprandial state was mostly 
performed in the triglyceride-rich lipoprotein fraction (ρ <1.006 g/mL) by using either 
density gradient or sequential ultracentrifugation to separate lipoproteins based on 
differences in density. Since lipoprotein substances have a relatively low density, they will 
float after following ultracentrifugation in a solvent of greater density. By overlaying plasma 
with a known density solution and performing ultracentrifugation lipoprotein particles with 
density less than the density solution will float to the top and can be isolated (Mills et al., 
1984).  
 Classically circulating chylomicrons are commonly identified by using density (ρ) < 
1.006 g/mL (Mills et al., 1984; Su, Nzekwu, Cabezas, Redgrave, & Proctor, 2009). To produce 
various fractions of TRL, speed and time of ultracentrifugation are modified resulting 
lipoprotein fraction of Sf >400 (mostly contains nascent chylomicrons), Sf 20 – 400 (mostly 
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VLDL), Sf 12 – 20 (mostly IDL) and Sf 0 – 12 (mostly LDL) (K. G. Jackson & Williams, 2004). 
However, the use of TRL subfractionation is hampered by the findings that only small-sized 
chylomicrons can enter the arterial wall therefore determination of chylomicrons in ρ 
<1.006 g/mL may not capture remnant particles at ρ >1.006 g/mL (Figure 5). 
 
Figure 5. Density distribution of chylomicrons and VLDL in plasma compartment. This figure 
shows the size distribution of chylomicrons and VLDL from secretion to clearance/vascular 
exposure. Measuring chylomicrons in TRL fraction may not capture the small dense 
chylomicron remnants. 
Source: Adaptation from Figure 2, Su et al (2009) (Licence number: 3937601209723) 
 To detect the presence of chylomicrons, there are several direct (sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), immunoblotting and enzyme-
linked immunoabsorbent assays (ELISA)) and indirect methods (retinyl esters). The 
approach used in the direct methods is by detecting the presence apo B-48, a unique and 
non-transferable apolipoprotein contained chylomicron particle (Phillips et al., 1997). SDS-
PAGE, a combination of staining and densitometric scanning, is the most widely method 
used for detecting chylomicron. However the use of this method may be limited by the 
multi-step process with no general protocol. Moreover the inter-assay variability between 
studies are large (Su et al., 2009). Immunoblotting and ELISA were developed since 
monoclonal and polyclonal antiserum to apo B-48 were found (Lorec et al., 2000; Uchida, 
31 
 
Kurano, & Ito, 1998). Immunoblotting has been widely accepted as one of the most 
sensitive and accurate method in quantifying apo B-48 however the impracticality (multi-
step and time consuming) to apply the method on large cohort may limit its usage (Su et al., 
2009). ELISA is introduced to generate a high throughput approach. The original procedure 
of ELISA is a competitive ELISA developed by Lorec et al (2000). In this procedure, the 
samples are pre-incubated with appropriate detergent and the plate is coated with apo B-
48 antiserum. Concentration of apo B-48 is inversely proportional to the amount of apo B-
48 antiserum bound on the plate (Lorec et al., 2000). Sakai et al (2003) developed sandwich 
ELISA. In this method, monoclonal anti apo B-48 antiserum is coated onto the wells of ELISA 
plate. Following incubation of diluted samples and washing, antigen (apo B-48) binds to the 
antibody. After the antigens are immobilized, a second monoclonal antibody linked to 
enzyme binds to the immobilized antigen (biotin-conjugated anti-apo B-48 antibody and 
peroxidise-conjugated streptavidin). The final step is adding substrate which is converted by 
the enzyme into a coloured product (Figure 6). Apo B-48 concentration is directly 
proportional to the amount of apo B-48 bound to the monoclonal antiserum (Sakai et al., 
2003). The advantage of ELISA method is the high specificity in detecting apo B-48 and the 
feasibility to use in large samples. However the influence of storage and preparation of the 
samples on the exposure of immunogenic sites on apo B-48 need to be considered (K. G. 
Jackson & Williams, 2004).  
 In this thesis, a combination of sequential flotation ultracentrifugation and 
sandwich ELISA developed by Sakai et al (2003) (Sakai et al., 2003) was performed. With 
this method, the distribution of apo B-48 in lipoprotein fraction can be quantified and, by 
extension, may capture the apo B-48 in the pro-atherogenic fraction. 
 
Figure 6. Schematic figure of apo B-48 sandwich ELISA. Y: antigen;  : antigen; : biotin-
conjugated anti-apo B-48 antibody;  : peroxidise-conjugated streptavidin; : substrate. 
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Source: Adaptation from http://www.elisa-antibody.com/ELISA-Introduction/ELISA-Principle. 
  
1.9.3 Postprandial chylomicron response 
The acute and chronic effects of dietary fatty acid composition on TRL postprandial 
response has been investigated in a number of studies. These are shown in Table 1.2. All 
these studies compared triglyceride and/or lipoprotein responses to an oral fat challenge of 
differing fatty acid challenge. The changes in triglyceride, apo B-48 or retinyl ester 
concentration in a number of lipoprotein fractions ranging from Sf >1000 to Sf 0 – 20 
fraction or ρ (density) <1.006 g/mL to ρ =0.019 g/mL were reported in those studies. 
In the less dense fraction (Sf >400 or ρ <1.006 g/mL), it is consistently shown that 
meals rich in MUFA induced increased postprandial response of either triglyceride, apo B-
48 or retinyl esters whereas inconsistent findings (greater, similar or smaller compared to 
MUFA) were observed in SFA and PUFA meal challenge. Acute meal studies in humans and 
Caco-2-cells, a human colon carcinoma cell line, have shown to induce larger particles size 
and numbers following exposure/ingestion of oleic acid (K. G. Jackson, D. M. Robertson, B. 
A. Fielding, K. N. Frayn, & C. M. Williams, 2002a; Van Greevenbroek, Van Meer, Erkelens, & 
De Bruin, 1996; C. M. Williams et al., 2004). The production of larger particle size and 
numbers could be due to the modulation of apo B mRNA editing enzyme or MTP expression 
or activity (Van Greevenbroek, Robertus-Teunissen, Erkelens, & De Bruin, 1998; Van 
Greevenbroek et al., 1996).  
The meal effect on lipoproteins in the VLDL size and density (Sf 60 – 400 and Sf 20 – 
60 fractions) was inconsistent. A number of studies have reported increased postprandial 
triglyceride and/or apo B-48 concentration in VLDL fraction following MUFA and SFA 
challenge and a decrease postprandial triglyceride response when challenged with PUFA 
meal however others reported no significant postprandial response between the meals 
observed (K. G. Jackson, M. D. Robertson, B. A. Fielding, K. N. Frayn, & C. M. Williams, 
2002b; Mekki et al., 2002; Mero et al., 1998). The different findings may be contributed to 
differences in the dose of fat, type and fats used as the comparators, meal size, meal base, 
the presence of other nutrients and habitual diets used in those studies (Denis Lairon, 
2008).   
Of particular interest is the postprandial response in the dense fraction (Sf <20). 
Given the atherogenicity evidence of chylomicron remnants, only a number of studies 
examined apo B-48 postprandial response in IDL fraction or denser (de Bruin, Brouwer, van 
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Linde-Sibenius Trip, Jansen, & Erkelens, 1993; Demacker, Reijnen, Katan, Stuyt, & 
Stalenhoef, 1991; Lozano et al., 2012; Mero et al., 1998), a lipoprotein fraction collected by 
ultracentrifugation with density of 1.006< ρ <1.019 g/mL or Sf 12 – 20 (Cohn et al., 1999). 
PUFA meal induced a 43% lower apo B-48 IAUC in the dense fraction in ρ <0.019 g/mL 
compared to the SFA meal (Demacker et al., 1991), while other reported no significant 
difference in apo B-48 response in the dense fraction (Mero et al., 1998). De Bruin et al. 
(1993) demonstrated that the percent increase in postprandial apo B-48 remnant 
concentration (ρ = 1.006 – 1.019 g/mL) at 2 and 4 hours after the test meal was higher in 
MUFA meal than in PUFA meal in normolipidemic suggesting remnants rich in PUFA were 
removed faster from the circulation (de Bruin et al., 1993). The low response of apo B-48 in 
the dense fraction following PUFA meal could be due to the increase in lipolytic rate by LPL 
and preferential hepatic uptake by HL of PUFA-enriched chylomicrons (Kathleen M. Botham 
et al., 1997; Bravo et al., 1995; Rahman et al., 2000). The lower postprandial triglyceride 
response following PUFA meal can be due to repression of apo C-III gene and induction of 
LPL expression mediated by PPAR (Kliewer et al., 1997; Staels et al., 1998). 
 A greater postprandial apo B-48 response in the dense fraction following a test 
meal challenge has been reported to associate with the existence of CVD (Karpe, Steiner, 
Uffelman, Olivecrona, & Hamsten, 1994; M. Weintraub et al., 1996). Karpe et al. (1994) 
reported a strong correlation between postprandial apo B-48 response in Sf 20 – 60 and 
atherosclerosis progression score following an oral fat tolerance test (Karpe et al., 1994). 
Weintraub et al (1996) reported a greater retinyl palmitate response in the non-
chylomicron fraction (Sf <1000) (M. Weintraub et al., 1996).  
Exaggerated postprandial lipaemia also occurs in obesity, type-2 diabetes and 
metabolic syndrome. Individuals with visceral obesity exhibited a higher secretion rate and 
a lower catabolic rate of apo B-48 (Annette T. Y. Wong et al., 2014) leading to an 
exaggerated medium and small TRL postprandial response (Couillard et al., 1998, 1999). 
The effect of dietary fatty acid composition on postprandial chylomicron response in the 
dense fraction has been reported by Lozano et al. (2012). They investigated the 
postprandial response between normolipidemic subjects with high BMI and low BMI 
following olive oil meal, butter meal and walnut meal (Lozano et al., 2012). They reported 
that the high BMI group exhibited higher IAUC triglyceride both in large (ρ <1.006 g/mL) 
and small TRL fraction (ρ =1.006 – 1.019 g/mL) compared to the low BMI group. Olive oil 
consumption induced a lower apo B-48 IAUC in the small TRL fraction irrespective of the 
BMI status. This finding was contradictory with the finding by de Bruin et al. (1993) 
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demonstrating increased postprandial apo B-48 remnant concentrations following a MUFA-
rich meal than that of PUFA-rich meal in normolipidemic men (de Bruin et al., 1993). It is 
possible that genetic variation, such as apo E polymorphism, may play a role in the 
differences in apo B-48 response (Bergeron & Havel, 1996; Ooi, Watts, Ng, & Barrett, 2015).  
Dai et al. (2009) reported that the average triglyceride concentration during 
postprandial state in Sf 20 – 60 fraction was lower in equidominant meal (a meal with equal 
proportion of SFA, MUFA and PUFA) and PUFA meal than the MUFA meal indicating that by 
increasing PUFA ratio may attenuate the atherogenic lipoprotein profile in patients with 
type 2 diabetes (Dai et al., 2009). In that study, they did not performed apo B-48 
determination. The consumption of n-6 PUFA in overweight/obese men was shown to 
increase the fractional catabolic rate of hepatic lipoprotein remnants (Van Schalkwijk et al., 
2014). 
Based on the findings in the above-mentioned studies, it appears that dietary fats 
may exert a differential effect on apo B-48/triglyceride response in the dense fraction and 
this interaction is implicated by metabolic phenotype. However the evidence are limited 
and the findings are inconsistent. 
 
1.10 Concluding remarks 
 A large body of evidence including epidemiological, clinical, animal and cell studies verifies 
the atherogenicity of chylomicron/chyomicron remnants. However despite this, there is a 
dearth of studies investigating the metabolic determinants of elevated chylomicron 
concentrations. Furthermore given the variability in lipid metabolism and body fat 
distribution in subjects of differing ethnic background it is important to investigate these 
metabolic determinants in different population groups. In addition, although a number of 
studies have investigated the effects of dietary fatty acid composition on postprandial 
lipaemia and atherosclerosis risk, the lack of information about the combined effects of 
dietary fatty acid composition and exaggerated postprandial lipaemia on chylomicron 




Table 1.1  Human studies examining the association between apo B-48 and a range of metabolic parameters 
Authors Study details Apo B-48 measured by Results and comments 
(Sakai et al., 
2003) 
Study: cross-sectional and postprandial 
Aim: to evaluate the metabolism of chylomicron and 
chylomicron remnants in normolipidemic and 
hyperlipidemic subjects.  
Subjects: 335 normolipidemic Japanese (281 men and 54 
women, age  47±7 years) and 239 hyperlipidemic subjects 
stratified according to type of hyperlipidemia (type I, IIa, 
IIb, III, IV and V) 
Primary outcome: concentration of apo B-48 in each 
group using a novel ELISA system. 
Sandwich ELISA Ao B-48 concentration in normolipidemic 
subjects: 5.2 ± 3.8 µg/mL. 
Very high level of  apo B-48 level in type I, III 
and V (7 – 18 higher). 
Strong association between apo B-48 and TAG 
(r =0.45). 
No association between apo B-48 and total 
cholesterol. 
  
(Kinoshita et al., 
2009) 
Study: cross-sectional 
Aim: to evaluate the association between chylomicron 
remnant (measured as apo B-48) and MetS and to 
investigate factors regulating apo B-48 levels in fasting 
plasma. 
Subjects: 1349 rural Japanese, 528 men, 821 women, 
Sandwich ELISA Strong association between apo B-48 and TAG 
(r=0.53 in men and r=0.48 in women). 
Strong association between apo B-48 and 
HOMA-IR (r=0.51 in men and r=0.43 in women). 
Weak to moderate correlation between apo B-
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Authors Study details Apo B-48 measured by Results and comments 
63±13 years. 
Primary outcome: relationship of apo B-48 with serum 
lipids and MetS. 
48 and cholesterol profiles. 
Higher apo B-48 level in subjects with MetS. 
No information on lipid lowering medication 
exclusion criteria.  
(Hanada et al., 
2012) 
Study: cross-sectional 
Aim: to evaluate the performance of chemiluminescent 
enzyme immunoassay 
(CLEIA) and examine correlations between serum apoB-48 
level and other lipid parameters. 
Subjects: 6 controls and 273 clinical samples, Japanese. 
Primary outcome: performance of CLEIA and correlation 
between apo B-48 and lipid parameters. 
CLEIA High correlation between apo B-48 measured 
with CLEIA and ELISA. 
Strong correlation between apo B-48 and RLP 
chol. 
Higher apo B-48 level in subjects with MetS. 
 
(Sato et al., 2009) Study: postprandial study 
Aim: to characterise lipid profiles in fasting state in order 
to detect postprandial lipemia. 
CLEIA HTG group has higher concentration of TAG, 




Authors Study details Apo B-48 measured by Results and comments 
Subjects:24 normolipidemic subjects, age 22±2 years, 
male/female: 11/13. 
Primary outcome: TAG, remnant chol and TAG, apo B-48 
concentration fasting and postprandial. 






Table 1.2 Effect of different fatty acid composition on postprandial TAG and lipoprotein responses 




Type and Fats 
used 
Fatty acid composition Fat Findings 










53g Sf> 400 [TAG] ↓ equidominant vs MUFA. 
Sf 60 – 400 [TAG] ↓ equidominant vs MUFA. 
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Type and Fats 
used 
Fatty acid composition Fat Findings 
 
 






-MUFA diet (1:1.7:1.2) 
-PUFA diet (1:1.7:2.3) 
Sf 20-60 [TAG] ↓ Equidominant and PUFA vs 
MUFA. 
No apo B48 measurement  
 
(K. G. Jackson 












-mixture Palm oil (29 g)+ cocoa butter 
(21 g)(26.1 g SFA:19.5 g MUFA: 3.2 g 
PUFA) /50 g 
-Safflower oil (7.8 g: 8.2 g: 31.8 g) 
-Olive oil (7.1 g: 34.9 g: 5.9 g) 
50g Sf > 400 AUC and IAUC [TAG] ↓PUFA  vs 
MUFA and SFA. 
Sf>400 & Sf 60-400 AUC and IAUC [apo B-48] 
↑ MUFA meal.  
 
 
(K. G. Jackson 
et al., 2002a) 
Normolipidemic 
Crossover design 




-palm oil (50% SFA:40% MUFA: 10% n-
6 PUFA:0% n-3 PUFA)% by wt 
-safflower oil (11%:15%:74%:0%) 
40 g ↑ [apo B-48] at 300 min in olive oil vs other 
oil meals. 
↓response for the ratio of TAG to apo B-48 
and less marked postprandial change with 
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Type and Fats 
used 





-fish/safflower oil (19%:20%:39%:22%) 
-olive oil (17%:72%:11%:0%) 
time after olive oil than other oil meals. 
Meal effect for olive oil after the second meal 
 
(K. G. Jackson 




Sf 60-400,  
Sf 20-60 
Mixed meal  
-palm oil 
-safflower oil  
-fish oil  
-olive oil  
Test oils: 
-palm oil (50% SFA:40% MUFA: 10% n-
6 PUFA:0% n-3 PUFA)% by wt 
-safflower oil (11%:15%:74%:0%) 
-fish/safflower oil (19%:20%:39%:22%) 
-olive oil (17%:72%:11%:0%) 
40g ↑ Sf 60 – 400 [TAG] and [apo B48] (300 min) 
vs Sf >400. 
↑ Sf 60-400 IAUC apo B48 in palm oil, 
safflower oil and olive oil vs in Sf >400. 
↑ Sf >400 IAUC apo B48 in olive oil vs any of 
other dietary oils. 












-Butter (53.7% SFA:26.8% MUFA: 
19.5% PUFA)% by wt, 100 mg of chol 
-Olive oil (24.6%: 51.9%:21.0%), no 
40g Sf> 400 [TAG] ↓ on butter meal. 








Type and Fats 
used 




-Sunflower oil (25.5%:27.7%:48.2%), 
no chol 
-No fat (47.6%:27.1%:24.4%) 
 
No measurement of apo B-48 concentration 
(Mero et al., 
1998) 
Middle age non 
obese men 
 Crossover design 
Sf>400 
Sf 60-400  
Sf 20-60  
Sf 12-20  
Sf 0-12  
Mixed meal 
Soy bean oil, 
the other not 
mentioned 
Test meals: 
-mixed meals (64.5% SFA: 30.4% 
MUFA: 5.1% PUFA) 
-soybean oil (15.1%:25.9%: 59.0%) 
-cream (68.5%: 27.6%: 3.9%) 
63 g ↔ IAUC TAG between three meals in all 
fractions. 
↔ IAUC apo B48 between 3 FTTs in all 














-PUFA rich meal (12.6% SFA:33.9% 
MUFA: 53.5% PUFA) % by weight 




↔ PP TAG and CM between meals 
No measurement of apo B-48 concentration 
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Type and Fats 
used 
Fatty acid composition Fat Findings 
- butter  
- double cream 



















 -rapeseed oil 
- sunflower oil 
- palm oil 
-rapeseed oil (7% SFA: 63% MUFA: 
30% PUFA) % by mol 
-sunflower oil (11.1%:21.4%:67.5%) 
- palm oil (39.2%:46.8%:14.1%) 
17.4g 
breakfast 
63.6 g for 
lunch 
↔ in lipoprotein and apolipoprotein 
responses after 3 types of meals were 
consumed. 






Sf>1000 Mixed meal  
-butter 
Meals: 
-Butter (66.6% SFA) by weight 
40g ↑chylomicron retinyl palmitate/oleate and 








Type and Fats 
used 
Fatty acid composition Fat Findings 
-Olive oil 
-Sunflower oil 
-Olive oil (75.5% MUFA) 
-Sunflower oil (67% PUFA) 
-Fat free meal (1.3 g fat) 
↑ retinyl palmitate AUC for LCFA (olive and 
sunflower). 
Peaks: 3 hours for fat free meal, 2-3 hours for 
butter, and 4 hours for olive and sunflower 
oil. 
No apo B48 measurement 












 -soybean oil 
-olive oil 
Meals:  
-Soybean oil emulsion (20% wt:vol) 
-Olive oil emulsion (17% Olive oil, 3% 
soybean oil) 
-cream (in other study) 
25 g/m2 
(total dose: 
49±3 g fat) 
↑AUC and peak [RP] in olive oil emulsion 
(Sf>1000 fraction) vs soybean 
Earlier RP peak in 1.006<d<1.019 in olive oil 
emulsion 
↑ [ apo B-48] at 2 and 4 hours after olive oil 




Normolipidemic  -Sf>1000 Mixed meal 
 -unsalted 
Meals: 
-Control meal (energy-free soup plus 
80 g  ↑TAG IAUC butter meal vs olive oil meal in 
chylomicron fraction and non-chylomicron 
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Type and Fats 
used 
Fatty acid composition Fat Findings 




50g carbohydrate as white bread) 
-Butter meal (control meal + 100 g 
butter / 72% SFA) 
-Olive oil meal (control meal + 80 g 
olive oil / 74% MUFA) 
 
fraction 
↑[ RP] butter meal vs others in the CM-rich 
fraction 
 


















-Control meal (energy-free soup plus 
50g carbohydrate as white bread) 
-Butter meal (control meal + 100 g 
butter / 72% SFA) 
-Olive oil meal (control meal + 80 g 
olive oil / 74% MUFA) 
80 g  ↑TAG IAUC butter meal vs olive oil and 
control meals. 
↔ TAG IAUC between olive oil and butter 
meal in chylomicron rich and chylomicron 
poor fractions. 
 
No apo B48 measurement 
(Sakr et al., Normolipidemic  -Sf>400 Liquid Test meals: 60 g ↔ IAUC for TAG vegetable oils in 
chylomicron rich fraction and chylomicron 
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Type and Fats 
used 
Fatty acid composition Fat Findings 
1997) Crossover design -Sf 20-400 -sunflower oil 
-oleic sunflower 
oil 
-soya bean oil 
-grapeseed oil 
-beef tallow 
-sunflower oil meal (12.4% SFA: 20.3% 
MUFA: 67.3% PUFA) % by wt 
-oleic sunflower oil meal 
(8.8%:73.1%:18.3%) 
-mixed oil (11.3%: 39.0%: 49.7%), 
containing 420 g/kg sunflower oil, 150 
g/kg soyabean oil and 50 g/kg 
grapeseed oil 
-beef tallow (49.7%: 45.1%: 5.2%) 
poor fraction 
↓ IAUC TAG after beef tallow vs other meals 
in chylomicron rich fraction 
At 4 hour after the ingestion, chylomicron 
diameter larger to smaller: Sunflower oil, 
mixed oil, oleic sunflower oil and beef tallow; 
↔ at after 8 hours 
 





















- high oleic acid 
Test meals: 
-high in palmitic and myristic acids 
-high in palmitic acid 
-high in stearic acid 
-high in oleic acid 
41-47% 
(1g/kg BW) 
↔ [TAG] between fractions at 4 h. 
 
LCSFA stearic and palmitic acids resulted in 
↓in plasma total and chylomicron TAG after 
4 h than did the other test fats and the return 
to post-absorptive values was slower. 
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Type and Fats 
used 














-high in linolenic acid 
-high in trans fatty acid 
See table 1 in the article 
 
No apo B48 measurement 
(Zampelas et 
al., 1995)  
(Kim G. 













-low MUFA meal (17.2% SFA: 12% 
MUFA: 5% PUFA)% by energy 
-moderate MUFA (12.3%: 17.1%: 4.6%) 
-high MUFA (5.4%: 24.1%: 4.6%)  
40 g ↔ IAUC TAG between three meals. 
A biphasic TAG response was observed in the 








Type and Fats 
used 















-low MUFA diet (12% en MUFA) (20g 
SFA: 14 g MUFA: 5.7 g PUFA) /40 g 
-moderate MUFA diet  (17% 
MUFA)(14.6g: 20 g: 5.4 g) 
-high MUFA diet (24% MUFA)(6.3 g: 
28.3 g: 5.4 g) 
40 g ↔ AUC, maximum postprandial plasma 
concentrations and time to maximum 
postprandial plasma TAG and apo B48 
concentration between the three test meals. 














-SFA meal (21% SFA:12% MUFA: 3% 
PUFA) 
-PUFA meal (10%: 9%: 18%)  
90 g /day ↓AUC apo B-48 d<1.019 PUFA meal vs the 
SFA meal 










 -coconut oil 
-Palm oil 
Test meals: 
-SFA meal (oil blend= coconut oil 30 
g/100 g: palm oil 30 g/ 100 g: olive oil 
40 g ↔AUC TAG for both meals between 
Southern and Northern Europeans  
↔AUC apo B48 between meals in Southern 
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Type and Fats 
used 
Fatty acid composition Fat Findings 
-Olive oil 
-Sunflower oil 
30 g/ 100 g: sunflower oil 10 g/ 100 g) 
-MUFA meal (olive oil 100 g/100 g) 

















-lauric + myristic acid (LM) 
-palmitic acid (POL) 
-stearic acid (STE) 
31% ↑AUC TAG STE vs POL and LM 
 
No apo B48 measurement 





















- Olive oil meal (SFA:MUFA:PUFA =22% 
: 38%: 4% and 0.7% a-linolenic acid)  
- butter meal (35%:22%:4% and 0.7%) 
- walnuts meal (20%: 24%:16% and 
4%) 
60% ↑ I AUC for small TRL-TG in HW subjects in 
butter or walnut meals  
There are BMI effect and diet effect on small 
TRL-TG. 
Meal effect on large and small TRL apo B48. 
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Type and Fats 
used 
































Chapter 2  
The association of fasting chylomicron concentration with a range of 
anthropometric and lipid parameters: 
 A cross-sectional study 
 
 
Content of this chapter is covered by the manuscript: 
 
Irawati D, Mamo JCL, Dhaliwal SS, Soares MJ, Slivkoff-Clark KM, James AP (2016). Plasma 
triglyceride and an inverse association with high-density lipoprotein cholesterol are poor 
surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with 
the metabolic syndrome. Lipid and Health Disease, In press. 
 
 
Thesis objective addressed in this chapter: 






















Triglyceride level has been widely accepted as an independent risk factor for CVD 
(Hokanson & Austin, 1996). However it has been the subject of debate whether plasma 
triglyceride or the lipoprotein particles independently contributed to the higher risk of CVD. 
In the fasting state, there is a switch of function in delivering triglyceride to LPL expressing 
tissues from mainly intestinal TRL (chylomicrons) in the postprandial state to hepatic TRL. 
Thus circulating triglyceride concentration during fasting is attributed mainly from hepatic 
TRLs. In fasting, the production of chylomicron in enterocytes still continue however with 
practically no dietary fat absorbed, the released chylomicrons would be triglyceride-poor 
(C. Xiao et al., 2011).  
 There is growing evidence that fasting apo B-48 concentration, a unique marker of 
chylomicron particle number, is associated with the existence of atherosclerosis and 
coronary artery disease (Alipour, Valdivielso et al. 2012; Masuda, Sugimoto et al. 2012; 
Tomkin and Owens 2012). The finding of apo B-48 particles in rabbit and human 
atherosclerotic tissue (Nakano et al., 2008; Pal et al., 2003; Proctor & Mamo, 2003) 
indicates that post-hydrolysed chylomicron remnants are an important key player in the 
development of atherosclerosis. To enter and be retained in the subendothelial tissue, 
lipoproteins need to be small in size and selectively bind to the subendothelial matrix. A 
line of evidence has demonstrated that apo B-48 particles from circulation was detected in 
the dense lipoprotein fraction (Campos et al., 2005; Karpe, 2012), these particles have the 
ability to penetrate the arterial wall to preferentially become trapped within the 
subendothelial space (Mamo and Wheeler 1994; Proctor and Mamo 1996), and induce 
inflammation (Yu and Mamo 2000; Batt, Avella et al. 2004). 
 Elevated plasma triglyceride is generally utilized as an indicator for exaggerated 
postprandial lipaemia. In combination with low HDL cholesterol concentration, triglyceride 
serves as a marker for dyslipidaemia and thus cardiovascular risk. However plasma 
triglyceride concentration principally reflects the lipolytic cascade instead of an indication 
of post-hydrolysed atherogenic remnants accumulation. Indeed association between 
triglyceride and apo B-48 concentration has been reported (Kinoshita et al., 2009; Sakai et 
al., 2003; Sato et al., 2009) but these findings may be specific to a Japanese population. 
 The primary objective of this study was to explore the association between plasma 
apo B-48 concentration with metabolic and anthropometric parameters in Australian 
population. To investigate whether the association was reliant on an altered phenotype of 
MetS instead of the individual cardiometabolic parameters, we grouped the subjects based 
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on the presence of MetS. This also allowed the evaluation of whether the associations hold 
in individuals with MetS (Dekker et al., 2005; Galassi, Reynolds, & He, 2006; J. Wang et al., 
2007). Previous studies have reported a greater fasting concentration of apo B-48 in 
individuals with MetS (Hanada et al., 2012; Kinoshita et al., 2009; Masuda et al., 2014). 
 
2.1.2 Methods in brief 
Two hundred and fifteen Australian Caucasian participants were randomly selected from a 
larger cross-sectional study conducted at Curtin University in 2011. Participants receiving 
lipid lowering medication were excluded. This study has been approved by Curtin University 
Human Research Ethics Committee (HR97/2011). The primary outcome of this study is the 
association between apo B-48 concentration with a range of measures of metabolic and 
anthropometric parameters. MetS criteria was based on Alberti et al (2009) (Alberti et al., 
2009). 
   
2.1.3 Results in brief 
Apo B-48 concentration was strongly correlated with triglyceride concentration (manuscript 
Table 3). Moderate association between apo B-48 with non-HDL cholesterol was observed. 
Apo B-48 was inversely correlated with HDL cholesterol concentration. Whereas apo B-48 
was weakly associated with total cholesterol and a range of anthropometric parameters 
(waist circumference and WHR). We also found that apo B-48 concentration was not 
associated with either insulin concentration or HOMA-IR level. When we adjusted for age 
and gender, the contribution of those parameters on the variability of apo B-48 
concentration was low (Table 2.1 in the Supplementary result section). Subjects with MetS 
exhibited an enhanced association of apo B-48 with triglyceride, total, non-HDL and LDL 
cholesterol than those without MetS (manuscript Table 4). 
 
2.1.4 Discussion and conclusion in brief 
The findings of this study confirm previous reports that fasting apo B-48 concentration is 
strongly associated with triglyceride concentration. In subjects with MetS, who have higher 
basal apo B-48 concentration, the slope of the association of Z scores for apo B-48 with 
triglyceride and non-HDL cholesterol and the coefficient of variation were increased 
compared to the non-MetS subjects. However these measures give no indication of 
chylomicron remnant homeostasis, which are our primary concern given the evidence of 
their atherogenicity. The reduced HDL cholesterol concentration observed in MetS was not 
associated with the increase in apo B-48 concentration, suggesting that factors 
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independent of chylomicron metabolism such as insulin resistance are possible (Rashid, 
Watanabe, Sakaue, & Lewis, 2003).  
Elevated triglyceride concentration in MetS suggests a lipolytic alteration that is 
augmented by insulin resistance (Annuzzi et al., 2008). Altered lipolysis leads to an 
increased residency time for chylomicrons and VLDL in the circulation and thus favours 
increased exchange of lipid between lipoproteins to result in accumulation of cholesterol-
rich remnants (Charles & Kane, 2012; Mann, Yen, Grant, & Bihain, 1991).  
Our findings suggest the importance of assessing TRL remnants. Defect in the 
metabolism and clearance of triglyceride rich lipoproteins are likely contributing to 






















































































































Table 2.1 The association between Z score of apo B-48 and anthropometric and 
lipid/metabolic determinants, after adjustment for age and sex  
 
Variables Total 
Triglyceride* 0.58 (p<0.0005, R2=0.304) 
Non-HDL cholesterol 0.353 (p<0.0005, R2=0.167) 
Glucose* 0.009 (p=0.911, R2=0.058) 
LDL cholesterol 0.269 (p<0.0005, R2=0.117) 
Cholesterol 0.275 (p<0.0005, R2=0.118) 
HDL cholesterol* -0.232 (p=0.002, R2=0.1) 
Waist circumference* 0.17 (p=0.023, R2=0.08) 
WHR 0.242 (p=0.007, R2=0.09) 
Systolic* -0.034 (p=0.641, R2=0.058) 
SAD 0.142 (p=0.053, R2=0.073) 
BMI 0.082 (p=0.211, R2=0.064) 
CRP 0.038 (p=0.556, R2=0.059) 
Insulin 0.083 (p=0.362, R2=0.061) 
Diastolic* 0.001 (p=0.997, R2=0.057) 
HOMA-IR 0.094 (p=0.391, R2=0.061) 
 
Regression coefficient represents the standard deviation change in apoB-48, as a result of 1 standard 
deviation change in the variable. Cells represent: slope estimate (p-value for estimate, R2 for model 
after adjustment). Significant associations are in bold font. *Variable use to determine the presence 






































Content of this chapter is covered by the article: 
 
Irawati D, Mamo JCL, Soares MJ, Slivkoff-Clark KM, James AP (2015). Hypertriglyceridemic 
subjects exhibit an accumulation of small dense chylomicron particles in the fasting state. 
Atherosclerosis, 243(1), 236-241. 
 
 
Thesis objective addressed in this chapter: 
Objective 2: To examine the abundance and size distribution of chylomicron particles in 






















3.1 Synopsis  
3.1.1 Background  
In the previous chapter, we reported a strong association between fasting apo B-48 and 
triglyceride concentration (see chapter 2) and concluded that the mechanisms of increased 
CVD risk induced by fasting hypertriglyceridemia remain unresolved. It is suggested that the 
increased triglyceride level is associated with elevated cholesterol-rich remnant 
lipoproteins, of which one of the contributors is the cholesterol-rich chylomicron remnants. 
A high fasting concentration of apo B-48 in the circulation is associated with the 
prevalence of coronary artery disease (Alipour et al., 2012; Masuda et al., 2012). According 
to the Response-to-Retention theory, atherogenesis is initiated by trapping of cholesterol-
rich lipoproteins in the subendothelial matrix (K. J. Williams & Tabas, 1995; K. J. Williams & 
Tabas, 2005). This suggests that particle size and binding selectivity are critical in remnant 
delivery and retention in the intima. The ability of chylomicron remnants to enter intimal 
tissue (Mamo, Proctor, & Smith, 1998), bind artery wall proteoglycans (Flood et al., 2002; 
Proctor et al., 2002) and induce foam cell formation through lipid enrichment in 
macrophages is well reported (Napolitano et al., 2001; Proctor & Mamo, 1996; Proctor et 
al., 2002; van Lenten et al., 1985). Furthermore, apo B-48 has been found in human 
atherosclerotic plaque (Nakano et al., 2008; Pal et al., 2003). 
Conventionally, the quantification of chylomicrons is performed in TRL fraction (Sf 
>400). This fraction consists of the large lipoproteins rather than the small, dense remnants 
that have a greater potential to deliver cholesterol to the subendothelial matrix and 
contribute to atherosclerotic plaque. This chapter investigates the concentration and size 
distribution of chylomicron in subjects with and without hypertriglyceridemia. 
 
3.1.2 Methods in brief 
Twelve hypertriglyceridemic and twelve age and gender matched normotriglyceridemic 
subjects were sampled from a larger cross-sectional study performed at Curtin University in 
2011. The subjects were selected randomly by an external statistician. The criteria for 
hypertriglyceridemia followed the NCEP-ATP III criteria (fasting triglyceride ≥ 1.7 mmol/L). 
The primary outcome of this study was the apo B-48 concentration in the following 
lipoprotein fractions: Sf >400, Sf 20-400 and Sf <20. Lipoprotein fractionation is detailed in 
the Supplementary Method section within this chapter. Ethics was approved by Curtin 





3.1.3 Results in brief 
Hypertriglyceridemic subjects exhibited a two-fold higher concentration of serum apo B-48-
containing lipoproteins compared to those with a normal triglyceride concentration 
(manuscript Figure 1A). In both groups the majority of apo B-48 was present in the Sf <20 
fraction but subjects with hypertriglyceridemia had a greater accumulation of these dense 
particles. The apo B-48 concentrations of the less dense fractions (Sf >400 and Sf 20-400) 
were also higher in the hypertriglyceridemic subjects. 
In subjects with a higher serum triglyceride concentration the triglyceride particles 
were distributed evenly in each fraction (manuscript Figure 2A). Conversely in 
normotriglyceridemic subjects the majority of triglyceride particles were in the dense Sf <20 
fraction. The estimated lipoprotein size as indicated by triglyceride to apo B ratio was 
greater in the less dense fraction (Sf >400 and Sf 20-400) in subjects with 
hypertriglyceridemia (manuscript Figure 3). No difference in serum cholesterol and NEFA 
concentration between groups was observed. 
  
3.1.4 Discussion and conclusion in brief 
Normocholesterolemic hypertriglyceridemic subjects in our study exhibited an 
accumulation of small-sized chylomicron particles in fasting plasma. We suggest that this 
accumulation is due to defective catabolism and/or clearance of those particles rather than 
as a result of increased chylomicron production. Further, we postulate that insulin 
resistance of the hypertriglyceridemic subjects in this study contributed to the defective 
catabolism and uptake of remnants by the liver. Insulin resistance triggers hepatic 
expression of SULF2 that leads to augmented HSPG de-sulfation in the liver (Chen et al., 
2009; K. J. Williams & Chen, 2010) which is a suggested mechanism that could account for 
the higher accumulation of dense apo-B48-containing particles. 
Even though the fasting triglyceride concentration and the triglyceride to apo B 
ratio in the less dense fraction were higher in hypertriglyceridemic subjects, there was no 
difference in serum NEFA concentration between the groups. Chylomicrons secretion from 
enterocytes relies on the availability of an intracellular lipid supply and insufficient 
lipidation of primordial particles will result in degradation of apo B-48. In fasting, primordial 
chylomicrons are lipidated from intracellular lipid supply which may derived from NEFA 
taken up from the circulation (Shojaee-Moradie et al., 2013). Since the hypertriglyceridemic 
subjects had a similar fasting NEFA concentration to normotriglyceridemic subjects, this 
supports our suggestion that the alteration in chylomicron metabolism was not at 
secretion, but more likely to be at the lipolysis or remnant clearance stages. 
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Our findings further substantiate the role of chylomicron remnants in mechanisms 
leading to CVD in hypertriglyceridemic subjects, in particular defective lipoprotein clearance 























































3.3 Supplementary methods 
 
Lipoprotein fractionation 
To separate and isolate lipoprotein fractions of serum samples, a sequential flotation 
ultracentrifugation method was used (Havel, Eder, & Bragdon, 1955; Anthony P. James & 
John C. Mamo, 2012). This technique fractionates lipoproteins by overlaying serum with 
NaCl density solutions adjusted to the fraction to be isolated. The flotation rate at which 
the centrifuged lipoproteins float to the top of the tube are a function of mass and 
hydrated density. 
The first step to estimating the time needed to float lipoprotein particles at certain 
flotation rate was to calculate ‘k’ value of the rotor in the desired spin (40,000 rpm), rmin 
and rmax (see in the AH-650 rotor guideline) by using the formula: 
 
𝑘 =
ln 𝑟𝑚𝑎𝑥−ln 𝑟𝑚𝑖𝑛 
3600 𝜔2
×1013  (equation 1) 
 
rmax for rotor AH-650 = 106.0 mm; rmin=62.8 mm; 𝜔 = 0.105 ×𝑅𝑃𝑀. So the k value for 
40,000 rpm in AH-650 rotor is 82.3. 
 The second step was to calculate the value of F. It should be noted that the F value 
must relate to the conditions in the preparative tube instead of using the conventional 
scale which is defined by analytical ultracentrifugation at 26C in NaCl solution of density 





 (equation 2) 
 
d represents the density of the lipoprotein particle and η represents the viscosity of a NaCl 
solution of density 1.006 g/mL at the temperature of the preparative ultracentrifugation. 




 (hours)   (equation 3) 
or 






    (equation 4) 
Ta = time to run in rotor A; ka = k value in rotor A at specific spin 




Using the above equations, the time taken to float lipoprotein particles of density Sf >400 
at 20C in the AH-650 rotor was 30 minutes, whereas to float Sf 20 – 400 particles took 20.5 
hours. 
 The preparation of density solutions followed the procedure developed by Lindgren 
(1975) (Lindgren, 1975). Briefly, to prepare a density solution with a density of 1.006 g/mL, 
11.45 g of NaCl was added to 1000 g double deionised water. To this solution, 100 mg of 
Na2EDTA and 1 mL of 1 M NaOH were added per litre of density solution. The final pH was 7 
and the density of the solutions were confirmed prior use. 
 
 
Figure 3.1 The plasma are overlayed with density solution. 
 
     
Figure 3.2 Cloudy appearance in the top layer of the samples (plasma and density solution) 
(left) and the supernatants collected (right). 
 
Ultracentrifugation was conducted using a Sorvall Ultraseries, rotor AH-650 at 
40,000 rpm and 20C. The procedure was as follows. One millilitre of plasma was overlayed 
with a density salt solution (1.006 g/mL) in 5 mL thin walled tubes (Thermo Scientific, 
Scoresby, Australia) until the liquid reached around 1 cm below the top (Figure 3.1). The 
ultracentrifuge tubes were placed into the buckets. The liquid was further added with the 
same density salt solution until it reached 2 mm below the top. The buckets and the lids 
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were weighed to ensure that the buckets were balanced. Subsequently the buckets were 
gently loaded into the rotor and the speed, temperature, time, and the type of rotor used 
for ultracentrifugation were set (Sorvall ultraseries, rotor AH 650). 
 
To float the Sf >400 lipoproteins, the samples were spun at 40,000 rpm at 20C for 
30 minutes. After spinning, the Sf >400 lipoprotein fraction (approximately 1 mL) was 
aspirated and placed into sterile tubes. Figure 3.2 shows that when the concentration of 
lipoprotein Sf >400 is high, the top layer will have a cloudy appearance. The infranatants 
were then topped up with the density solution until the liquid reached 2 mm below the top 
of the tube. The buckets were spun again for 20.5 hours at the same speed and 
temperature. During this spinning, large and small VLDL-sized particles float to the top of 
the tube, leaving lipoproteins Sf <20 in the infranatants. A similar method of collection by 
aspiration was applied (as above). The volume of all lipoprotein fractions and infranatants 
were measured using a 1 mL glass bore syringe (Hamilton). These volumes were used to 
calculate the amount of triglyceride and cholesterol in each lipoprotein fraction. After this 













































Chapter 4  
The effect of dietary fatty acid composition on plasma abundance of 
pro-atherogenic chylomicron remnants in postprandial hyperlipidemia 
 
 
Content of this chapter is covered by the manuscript: 
Irawati D, Mamo JCL, Soares MJ, Slivkoff-Clark KM, James AP. Dietary fat and physiologic 
determinants of plasma chylomicron remnant homeostasis in normolipidemic 
subjects: Insight into atherogenic risk. 
 
Under consideration for publication. 
 
 
Thesis objective addressed in this chapter: 
Objective 3: To investigate the acute effect of dietary fatty acid composition and metabolic 























The majority of humans spend most of their lives in the postprandial state. Following 
ingestion of dietary fats, there is an increase in triglyceride-rich chylomicrons however this 
elevation is temporary. Stimulated by insulin, LPL bound GPIHBP1 mediates the hydrolysis 
of triglyceride from TRL releasing NEFA to be taken up by the endothelial cells via CD 36 
(Geesje M. Dallinga-Thie et al., 2010). Eventually chylomicrons and VLDL become smaller 
forming remnant lipoproteins which are removed from the circulation mainly via receptor-
mediated pathway in the liver (Cooper, 1997).  
The increase in postprandial triglyceride concentration reflects the net effect of 
dietary absorption in the intestine, chylomicron assembly and secretion by the enterocytes 
and lipolysis by LPL. However previous evidence has shown that it is the remnant 
lipoproteins that are associated with atherogenicity (Mamo, Proctor et al., 1998). Indeed in 
Chapter 3, we found that in the fasting state the majority of apo B-48 containing 
lipoproteins were present in the Sf <20 fraction (Irawati, Mamo, Soares, Slivkoff-Clark, & 
James, 2015). However we observed that the distribution of chylomicron concentration was 
skewed indicating genetic variability in chylomicron metabolism either in the basal 
production rates and/or clearance of chylomicrons. 
A large body of evidence has reported the effect of dietary fatty acid on 
chylomicron remnant metabolism through modulation of chylomicron assembly (i.e. MTP 
activity, lipid droplet formation and stability), LPL preference and clearance rate (C. M. 
Williams, 1998; C. M. Williams et al., 2004). Amongst dietary fatty acids, SFA has been 
associated with atherogenicity through the poorly defined alteration in chylomicron 
metabolism, hypercholesterolemic effect and vascular inflammation (Esser, van Dijk, 
Oosterink, Müller, & Afman, 2013; Lamarche & Couture, 2015; Mensink, Zock, Kester, & 
Katan, 2003; Ruiz-Núñez, Dijck-Brouwer, & Muskiet, 2016). The type of dietary fats also 
influences the extent of postprandial lipemia (C. M. Williams, 1997, 1998; C. M. Williams et 
al., 2004), however most of the evidence examined the postprandial response in lipid-rich 
lipoprotein fractions, a rather than more dense fractions containing small-sized pro-
atherogenic remnants.  
In this chapter, we compared the chylomicron remnant postprandial response 






4.1.2 Methods in brief 
In this cross-over designed study, healthy normotriglyceridaemic subjects were recruited to 
receive in random order an isoenergetic mixed meal containing 40 g of either: palm oil (PO) 
(SFA:MUFA:PUFA=60%:31%:9%), coconut oil (CO) (SFA:MUFA:PUFA=92%:8%:0%), or rice 
bran oil (RBO) (SFA:MUFA:PUFA=28%:40%:32%) on 3 occasions. The plasma distribution of 
chylomicron apo B-48 was determined in a triglyceride rich lipoprotein fraction (Sf >400), in 
partially hydrolysed remnants (Sf 20 – 400) and in the triglyceride deplete fraction (Sf <20). 
The detail of the lipoprotein fraction has been explained in Chapter 3 (Supplementary 
method).  
The primary outcome of this study was the apo B-48 IAUC in subjects with 
exaggerated plasma triglyceride (≥1.7 mmol/L) 4 hours after consuming the dietary 
challenge rich in PO (hyper-responders/HR) compared to subjects with plasma triglyceride 
less than 1.7 mmol/L at the peak of the absorptive period (normal responders/NR). Ethics 
was approved by Curtin University Human Research Ethics Committee (HR 151/2013). The 
trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN 
12614000352606). 
  
4.1.3 Results in brief 
Twenty-six normotriglyceridemic subjects participated in the study. In fasting, around 74% 
of the chylomicrons was in the Sf <20 fraction (apo B-48 in plasma: 8.3 ± 1.2 µg/mL, in Sf 
>400: 0.7 ± 0.2 µg/mL, in Sf 20-400: 1.5 ± 0.2 µg/mL and in Sf <20: 6.2 ± 0.9 µg/mL, 
respectively).  
Approximately 40% of subjects exhibited exaggerated postprandial lipaemia 
following the PO meal (HR group)(recruitment flow diagram in the Supplementary section). 
No difference in fasting apo B-48 concentration was observed between the hyper-
responders and normo-responders (manuscript Table 2).  
 Following the PO meal, approximately three-fold higher plasma apo B-48 IAUC was 
observed in the HR group compared to the NR group with half of the exaggerated apo B-48 
response residing in the remnant Sf <20 fraction (manuscript Figure 1). A smaller increase in 
apo B-48 response within the Sf 20 – 400 and Sf >400 fraction was also observed in the HR 
group compared to that of the NR group. The IAUC apo B-48 response following either RBO 
or CO meal was comparable in both groups. 
 In the HR group, fat free mass was associated with IAUC apo B-48 in Sf >400 and Sf 
20 – 400 fraction but not with Sf <20 across all meal challenges. In contrast, no significant 
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association between IAUC apo B-48 in any of the lipoprotein fraction with fat free mass was 
observed in the NR group. Fasting triglyceride concentration was not associated with any of 
the lipoprotein fractions across all dietary treatment arms in the HR group. 
 
4.1.4 Discussion and conclusion in brief 
Contrary to the conventional thought, the majority of chylomicron particles in the fasting 
state and their response in the postprandial state are found within the potentially pro-
atherogenic Sf <20 fraction. This suggests that following dietary fat ingestion, a substantial 
proportion of circulating chylomicrons can directly penetrate the subendothelial space.   
 The results of this chapter showed that the magnitude of hyper-remnantemia is 
dependent both on the nature of dietary fatty acids ingested and genetic determinants. The 
greater postprandial chylomicron response following PO meal observed in a subset of 
normotriglyceridemic subjects but not in the NR group indicates differential expression of 
key apolipoproteins (i.e. apo C-II, apo C-III, apo E) or isoforms of lipolytic enzymes involved 
in lipolysis. However this may not be the case as the chylomicron and triglyceride 
postprandial responses were comparable following ingestion of either CO or RBO meal 
suggesting intact lipolysis/clearance machinery.  
The association between apo B-48 and fat free mass index (inverse in fat mass 
index) suggests the possibility of modest hydrolytic defect in muscle tissue. It is possible 
that the defect is more pronounced when the subjects ingested PO meal. Ingestion of a 
meal rich in SFA content has been reported to decrease insulin sensitivity (Galgani, Uauy, 
Aguirre, & Díaz, 2008; Riccardi, Giacco, & Rivellese, 2004) via accumulation of diacylglycerol  
and ceramide in muscle, activation of protein kinase C, nuclear factor-KB and the 
subsequent inflammatory genes (Kennedy, Martinez, Chuang, Lapoint, & McIntosh, 2009).  
Our findings reiterate the importance of assessing remnant lipoprotein 
concentration. The classical markers of plasma lipid homeostasis measured in this study 
provide no valuable insight into chylomicron metabolism and remnant homeostasis. 


















































































































Figure 1. Participant recruitments flow diagram. Twenty-six participants were included in 
the data analysis. Of them, three subjects only attended 2 postprandial visits (2 subjects did 
not attend PO meal visit and a subject did not attend CO meal visit). Those who did not 

















































Chapter 5: Discussion, limitations and future studies 
 
This chapter provides a general discussion of the findings presented in Chapter 2, Chapter 3 
and Chapter 4. In the study described in Chapter 2 the association between apo B-48 
concentration, a measure of chylomicron particle number, with a range of metabolic and 
anthropometric parameters was explored. Fasting chylomicron concentration was strongly 
associated with triglyceride concentration. Results outlined in Chapter 3 demonstrated the 
abundance and size distribution of chylomicrons in hypertriglyceridaemic and 
normotriglyceridaemic subjects. Furthermore in this study the contribution of an 
accumulation of chylomicron particles to the increased risk CVD in hypertriglyceridaemia 
was discussed. Whereas in Chapter 4 the effect of consumption of edible oil consumption 
(palm oil, coconut oil and rice bran oil) on postprandial chylomicron metabolism was 
investigated in a group of normotriglyceridaemic subjects. In this chapter the potential 
mechanism by which dietary lipids may regulate chylomicron remnant metabolism is 
discussed in relation to increased risk of atherosclerosis. 
   
5.1 Chylomicron remnant metabolism and atherosclerosis 
A central paradigm for the current atherogenesis model is the retention of lipoproteins in 
subendothelial tissue (K. J. Williams & Tabas, 1995; K. J. Williams & Tabas, 2005). Sustained 
concentration of remnant lipoproteins, particle size (Shaikh et al., 1991; M. Simionescu & 
Simionescu, 1991; Stender & Zilversmit, 1981; D. B. Zilversmit, 1995) and selectivity to the 
proteoglycans are crucial factors influencing chylomicron deposition in the subendothelial 
tissue (Flood et al., 2002). Indeed the preferential entrapment of apo B-48 containing 
lipoproteins in subendothelial tissue and detection of apo B-48 containing lipoproteins in 
animal and human atherosclerotic tissue have been reported (Nakano et al., 2008; Pal et 
al., 2003; Proctor & Mamo, 2003; Proctor & Mamo, 1996).  
The presence of remnant lipoproteins in the subendothelial tissue will activate 
monocytes via several mechanisms: accumulation of cytosolic lipid droplets (Bentley et al., 
2011), upregulation of apo B-48 receptor mRNA expression (Bermudez et al., 2012; Varela 
et al., 2011) and LRP1 (Gower et al., 2011), increase expression of leukocyte activation 
markers (CD11b) (Alipour et al., 2008), upregulation of a number of markers related to 
monocyte adhesion (Gower et al., 2011; Kawakami et al., 2002), increased production of 
reactive oxygen species (Bentley et al., 2011) and modulation of migratory and chemotaxis 
markers (IL-8, MCP1) (Bentley et al., 2011). These mechanisms result in migration and 
adherence of monocytes to the endothelium.  
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In subendothelial tissue, chylomicron remnants are taken up by macrophages via 
receptor-mediated LDLR and LRP1 apo E-dependent (Bejta et al., 2007), apo B-48R apo B-
dependent (M. L. Brown et al., 2000),  scavenger receptor CD36 (Bejta et al., 2007) and 
non-receptor mediated pathway via LPL (K. M. Botham & Wheeler-Jones, 2013; Palmer et 
al., 2005). The uptake of chylomicron remnants via phagocytosis has also been reported 
(Bejta et al., 2007; Elsegood & Mamo, 2006; Mamo et al., 1996). The lipid (mainly 
cholesteryl ester) originating from remnants will be esterified and stored in macrophages 
intracellularly forming foam cells. When these foam cells accumulate, fatty streaks, the 
hallmark of atherosclerosis, will be formed. 
 
5.2 Metabolic determinants associated with chylomicron metabolism  
Given accumulated evidence on chylomicron atherogenicity, remarkably studies that 
investigate the association between chylomicrons and other metabolic parameters are 
limited and are specific to a Japanese population (Kinoshita et al., 2009; Sakai et al., 2003; 
Sato et al., 2009).  
 As described in Chapter 2, our findings confirmed the result of previous studies that 
apo B-48 was strongly associated with triglyceride concentration (Kinoshita et al., 2009; 
Sakai et al., 2003; Sato et al., 2009). However despite a strong association between apo B-
48 and triglyceride concentration, the contribution of triglyceride concentration to the 
variability of apo B-48 concentration adjusted for age and gender was low (30.4%). This 
suggests that triglyceride concentration is a poor surrogate marker of chylomicron remnant 
metabolism. The implication of this suggestion is that a subset of normotriglyceridaemic 
individuals may have an increased chylomicron concentration, and by extension, a higher 
atherogenic risk, however their susceptibility to develop atherosclerosis may not be 
detected by the conventional blood / health screening. 
 A greater fasting apo B-48 concentration has been reported in individuals with 
MetS (Hanada et al., 2012; Kinoshita et al., 2009; Masuda et al., 2014). Alterations in 
chylomicron metabolism that lead to an accumulation of chylomicron remnants are poorly 
defined. However evidence from animal models and insulin resistant subjects 
demonstrated that the aberration of chylomicron metabolism in MetS is due to an 
increased production rate of chylomicrons as a consequence of intestinal hypertrophy 
(Duez et al., 2006) and reduced lipolysis due to a decrease in LPL expression (Annuzzi et al., 
2008). In Chapter 2, the extent of association between apo B-48 and triglyceride was higher 
in subjects with MetS; nonetheless triglyceride concentration was still not predictive of 
chylomicron homeostasis. The low coefficient of variation for slope of association between 
103 
 
Z scores of apo B-48 and triglyceride in the total population (both MetS and no-MetS group) 
indicates that triglyceride is a poor surrogate marker of chylomicron homeostasis. 
In addition to triglyceride concentration, decreased HDL cholesterol concentration 
has been recognised as a marker for increased CVD risk. The findings in Chapter 2 
demonstrated that after adjustment for gender and age, there was no association between 
apo B-48 and HDL cholesterol concentration irrespective of the presence of MetS. This 
suggests that independent factors may implicate HDL cholesterol concentration (i.e. insulin 
resistance) (Li et al., 2014; Rashid et al., 2003). 
The possibility of LDL cholesterol concentration as a predictor for remnant 
accumulation was also evaluated. Elevated triglyceride concentration in MetS is an 
indication of impaired lipolysis. Altered lipolysis promotes a longer residency time for TRL in 
the circulation and thus may affect lipid exchange and remodelling of lipoproteins. The 
increased transfer rate of cholesteryl ester from HDL to TRL would result in excessive 
cholesterol influx into the liver and eventually a build-up of cholesterol-rich chylomicrons 
due to down-regulation of LDLR (Tall, 1993). The clearance of these cholesterol-rich 
chylomicrons or chylomicron remnants by LDLR require a cluster of apo B/E receptors 
whereas LDL particles are cleared via a singular receptor interaction (Goldstein & Brown, 
2009; Mahley, 1988). Therefore LDL cholesterol would be a poor predictor for remnant 
accumulation.  
A strong association was also observed between apo B-48 and non-HDL cholesterol, 
a representation of cholesterol content in lipoproteins currently considered to contribute 
to atheroma development: chylomicron remnant, VLDL remnant and LDL particles (Blaha, 
Blumenthal, Brinton, & Jacobson, 2008; Miller, Ginsberg, & Schaefer, 2008). The strong 
correlation between apo B-48 and non-HDL cholesterol concentration indicates that 
accumulation of apo B-48 leads to the cholesterol enrichment in chylomicron remnants. In 
MetS where the CETP activity is increased, a greater proportion of cholesteryl ester would 
be diverted to TRL resulting in low cholesteryl ester content in HDL particles and an 
elevated concentration in acceptor lipoproteins (chylomicron and VLDL remnants) (Dullaart 
et al., 2011). The implication of this is that as chylomicron particles become smaller in size, 
they will carry more cholesterol and thus be more atherogenic (D. B. Zilversmit, 1995). 
These cholesterol-rich remnants can be sequestered by the arterial walls and induce the 
formation of lipid-laden monocytes/macrophages.  
The NCEP ATP III guidelines have included non-HDL cholesterol concentration as a 
secondary target therapy taking into account the atherogenic potential of remnants in 
hypertriglyceridaemic individuals with triglyceride concentration of more than 200 mg/dL 
104 
 
(5.17 mmol/L) (Grundy et al., 2004). The findings in Chapter 2 have demonstrated a strong 
association between apo B-48 and non-HDL cholesterol concentration in the MetS group in 
which the average triglyceride concentration was 1.7 mmol/L. Considering that a 1:1 
association between the percent of non-HDL cholesterol reduction and the percent of CVD 
risk reduction (Robinson, Wang, Smith, & Jacobson, 2009) and greater risk of myocardial 
infarction, ischemic heart disease and ischemic heart stroke in hypertriglyceridemic 
individuals (B. G. Nordestgaard, 2016) have been reported, it is possible that patients may 
benefit more from a lower triglyceride target.  
Elevated triglyceride, LDL cholesterol and low HDL cholesterol are generally utilised 
as markers for atherogenic dyslipidaemia and increased cardiovascular risk. However based 
on our findings, these parameters are not suitable surrogate markers to assess chylomicron 
remnant homeostasis. The importance of measuring apo B-48 concentration for 
atherogenic risk remains in particular in groups with higher CVD risk such as MetS.   
 
5.3 Chylomicron size distribution in hypertriglyceridaemia 
As described in Chapter 3, subjects with normocholesterolaemic hypertriglyceridaemia 
exhibited a greater apo B-48 concentration in all fractions with the majority of the 
increased apo B-48 being in the lipid-poor Sf <20 fraction. It is estimated that lipoproteins 
found in this fraction have a diameter of less than 55 nm (Mills et al., 1984), a pro-
atherogenic lipoprotein size phenotype (N. Simionescu & Simionescu, 1985). Accumulation 
of small-sized chylomicrons may partly explain the association between elevated fasting 
triglyceride concentration and increased risk of CVD. 
The mechanisms for this association could be via altered chylomicron lipolysis 
and/or removal from the circulation. The build-up of small-sized chylomicrons may be 
indicative of altered remnant uptake by the liver. This defect could be due to accelerated 
de-sulfation of liver HSPG induced by insulin resistance (Chen et al., 2009; K. J. Williams & 
Chen, 2010). Hepatic over-expression of SULF2 is responsible for the removal of 6-O-
sulfates from HSPG structure leading to cell surface and HSPG matrix degradation. 
We proposed the possibility that impaired chylomicron metabolism in 
hypertriglyceridaemia was due to delayed TRL lipolysis. This contention is based on the 
findings of a greater apo B-48 and triglyceride concentration in the lipid-rich fraction (Sf 
>400 and Sf 20 – 400) and larger triglyceride to apo B ratio as observed in Chapter 3 
indicating a larger lipoprotein size in that fraction (Ruderman, Richards, & Valles de 
Bourges, 1968). A defect in lipolysis would provide more opportunity for cholesteryl ester 
triglyceride exchange (Eisenberg, Gavish, Oschry, Fainaru, & Deckelbaum, 1984; Sniderman, 
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Tremblay, De Graaf, & Couture, 2012) leading to cholesterol enrichment in the TRL fraction 
(Sniderman et al., 2012). Our observation of a greater amount of cholesterol in the lipid-
rich fraction in the hypertriglyceridaemic group supports this contention. Impaired 
transcription of LPL gene may explain the delay in lipolysis mediated by insulin resistance 
(Maheux et al., 1997).  
From our findings in hypertriglyceridaemic subjects, it is unlikely that the 
accumulation of apo B-48 in the lipid-rich (Sf >400 and Sf 20 – 400) and lipid-poor (Sf <20) 
fractions was due to increased production rate of chylomicrons mediated by insulin 
resistance. In the fasting state, chylomicron production rates depend on the intestinal lipid 
availability such as from cytoplasmic lipid droplets (Shojaee-Moradie et al., 2013). The 
source of lipid within this droplets could be from previously ingested dietary fats or 
endogenous lipid (either from de novo lipogenesis or NEFA absorbed from circulation). We 
found no difference in NEFA concentration between groups. 
 
5.4 The effect of dietary fatty acid composition on chylomicron remnant accumulation 
The findings in Chapters 2 and 3 demonstrated a potential mechanism for the 
atherogenicity associated with hypertriglyceridaemia. We found that in the fasting state the 
majority of apo B-48 containing lipoproteins were present in the Sf <20 fraction (Irawati, 
Mamo et al. 2015). However the skewed distribution of chylomicron concentration 
suggests the possibility of genetic variability in chylomicron metabolism either in the basal 
production rates and/or clearance of chylomicron. 
 The findings in Chapter 4 confirm the results of Chapter 3 that showed the majority 
of apo B-48 in normotriglyceridaemic subjects in fasting was in the pro-atherogenic Sf <20 
fraction. In the postprandial state, the apo B-48 response was substantially contributed by 
the apo B-48 in the Sf <20 fraction. This finding highlights the substantial exposure of small-
sized pro-atherogenic chylomicron remnants on the arterial walls in the postprandial state.  
The surge of postprandial apo B-48-containing particles in the pro-atherogenic fraction 
signifies lipoproteins that can directly enter the subendothelial space. With the majority of 
time spent by humans in the postprandial state, this finding underscores the importance of 
postprandial remnantaemia on the increased CVD risk. 
The findings from the study described in Chapter 4 also demonstrate that the 
heterogeneity in the extent of hyper-remnantaemia is influenced by the nature of fatty 
acids and the genetic determinants of the response. We identified a subset of subjects who 
despite being normotriglyceridaemic in the fasting state exhibit elevated postprandial 
triglyceridaemia (HR, hyper-responder group). The HR group exhibited a substantial 
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accumulation of chylomicron particles in the pro-atherogenic Sf <20 fraction following PO-
derived SFA meal despite no evidence of chylomicron remnant accumulation in the fasted 
state. This implies an involvement of genetic determinants in chylomicron homeostasis in 
response to a meal. 
Since the exaggerated response was only observed following PO meal challenge, 
not when challenged with either RBO or CO meal, our interpretation is that the metabolic 
defect of the HR subjects is specifically associated with the metabolism of chylomicron rich 
in PO-derived fatty acids. The possible genetic point of synergistic regulation of PO-rich 
chylomicrons is either differential expression of key apolipoproteins involved in lipolysis 
(i.e. apo CII/CIII) or clearance (apo E isoforms) (Schwarzova, Hubacek, & Vrablik, 2016) or a 
modest defect in hydrolysis mediated LPL in the muscle tissue. Meals rich in SFA have been 
reported to decrease insulin sensitivity (Galgani et al., 2008; Riccardi et al., 2004) via 
accumulation of diacylglycerol and ceramide in muscle, activation of protein kinase C, 
nuclear factor-KB and the subsequent inflammatory genes (Kennedy et al., 2009). Therefore 
muscle mediated LPL activity may be have been attenuated in HR subjects  (Annuzzi et al., 
2008). In addition, SFA-rich meals also induce greater apo C-III expression compared to 
unsaturated fatty acid (K. G. Jackson et al., 2005). The possible involvement of 
increased/decreased lipolytic enzyme or the presence of isoforms of receptor clearance 
proteins is less likely given the comparable apo B-48 response between NR and HR groups 
in response to RBO or CO meal challenge.  
The current guidelines adopted by several countries have used nonfasting 
triglyceride concentration of 1.89 mmol/L or 2 mmol/L or more as the cut off for increased 
risk of CVD events. From our postprandial study, we observed that using a cut-off of plasma 
triglyceride concentration of 1.7 mmol/L or more at 4-hour postprandially was predictive of 
an accumulation of small-sized chylomicrons following a PO-rich meal challenge. 
These subjects would, according to the conventional CVD risk measures, have a 
very low risk of CVD. However our study provides evidence of a subset of these who exhibit 
impaired postprandial lipaemia following SFA-rich meals with an increased CVD risk 
expected due to an accumulation of postprandial chylomicron remnant particles. 
Furthermore, in this study, the classical markers of lipid homeostasis (triglyceride, HDL 
cholesterol, LDL cholesterol and non-HDL cholesterol) were within normal range in both NR 
and HR groups and those markers were not associated with apo B-48 response. This implies 
that those markers provide no valuable insight into chylomicron remnant metabolism and 





An increased concentration of plasma triglyceride has been widely accepted as an 
independent risk factor for CVD. However it is unclear whether the higher risk of CVD is 
attributed to plasma triglyceride or the lipoprotein particles on which it resides. A large 
body of evidence has demonstrated the atherogenicity of chylomicrons/chylomicron 
remnants in animal models and human studies. To initiate atherogenesis, lipoproteins need 
to be retained in the subendothelial tissue. Obligatory properties for trapping remnants in 
the subendothelial matrix include a sustained concentration, appropriate particle size and 
selectivity of lipoproteins to subendothelial proteoglycan. Alterations in chylomicron 
assembly, lipolysis and clearance affect the particle size and the concentration in the 
circulation. The type of dietary fats is also known to affect lipid partitioning, lipolysis and 
clearance rate. Hence studies included in this thesis explored the interaction between 
metabolic determinants, dietary fats and chylomicron metabolism, specifically taking into 
consideration the distribution of apo B-48 in lipoprotein fractions. 
 Our observation confirmed that the fasting apo B-48 concentration, a measure of 
chylomicron particle number, was strongly associated with the fasting triglyceride 
concentration. We noted a stronger association in subjects with MetS. The well-reported 
relationship between elevated fasting triglyceride concentration and a higher risk of CVD 
may partly be explained by our observation of a chylomicron build-up in subjects with 
hypertriglyceridaemia including large and the small-sized pro-atherogenic remnants.  
 The association between apo B-48 the measured cholesterol profiles was variable. 
Apo B-48 was moderately or weakly associated with non-HDL cholesterol and HDL 
cholesterol concentration. In individuals with MetS, the association between apo B-48 
concentration and non-HDL concentration was stronger whereas the association with HDL 
cholesterol was not significant suggesting independent factors implicate HDL cholesterol 
concentration. However those parameters (HDL cholesterol and non-HDL cholesterol) were 
poor surrogate markers for chylomicron homeostasis due to the low contribution of those 
markers on the variability of apo B-48 concentration. The need to measure apo B-48 
concentration to determine atherogenic risk remains, especially in population with higher 
CVD risk such as in MetS. 
In the postprandial state, the substantial chylomicron response is within the pro-
atherogenic Sf <20 fraction indicating that following ingestion of fatty meal a considerable 
proportion of chylomicrons are able to directly enter the arterial walls. We also found that 
some healthy normotriglyceridaemic individuals (hyper-responders) exhibited exaggerated 
chylomicron remnantaemia in response to a meal rich in SFA derived PO substrate but not 
108 
 
when challenged with RBO or CO meal. This indicates the synergistic regulation between 
physiologic/genetic determinants and the nature of fatty acids.  
The greater proportion of circulating apo B-48 in the dense fraction (Sf <20) 
observed in both fasting and postprandial states puts individuals at risk of exposure of small 
sized remnants on the vascular bed. In conditions where clearance of chylomicron 
remnants is altered, such as hypertriglyceridaemia, the exposure is heightened. However 
the concentration of circulating remnants cannot be predicted by the classic metabolic 
parameters or components of MetS. Furthermore we also found that some 
normotriglyceridaemic individuals exhibit silent hyper-remnantaemia in response to PO-
enriched meals but not in others suggesting interactive effects of dietary fatty acid 
composition on remnant chylomicron response. Therefore our findings underscore the 
importance of examining chylomicron metabolism especially in people with heightened risk 
of CVD. 
 
5.6 Limitation of the studies 
There are limitations to the design and some of the methodologies in this thesis which need 
consideration. The cross-sectional study design in Chapter 2 provides strong associations 
but future intervention trials are needed for causative interpretation of our outcomes. In 
Chapter 4, we used PO meal challenge to assign subjects into hyper- and normo-responder 
group instead of utilising the commonly used liquid formula for fat tolerance test (Kolovou, 
Mikhailidis et al. 2011). This allowed us to test the response to a mixed meal (~40 g fat) that 
may typically be consumed by free living individuals (Silva, Wright et al. 2005). Consuming 
75 g fat for assessing postprandial lipaemia as suggested may have overshadowed subtle 
differences due to an exaggerated postprandial response (Lairon 2008). In the postprandial 
study (Chapter 4), the postprandial response was assessed based on the changes in 
triglyceride or chylomicron concentration measured at three time points (0, 4 and 8 hours). 
The limited number of time points for the postprandial blood collection could have affected 
the calculation of the postprandial response if the postprandial peak was missed. However 
we chose three blood collection time points to minimise participant discomfort, given the 
evidence of a high correlation between three and the conventional hourly time points in 
oral fat tolerance tests (Maraki, Aggelopoulou et al. 2011). 
The studies included in this thesis have used immunological based methods to 
quantify lipoprotein of interest, apo B-48. The limitation of this method is the potential of 
confounding effects originating from lipid interference with the binding of antibodies with 
protein epitopes. This would result in underestimation of protein concentration. In the 
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study in Chapter 3, there was a significant greater apo B-48 concentration between 
normotriglyceridaemic and hypertriglyceridaemic subjects. If there were lipid interference 
with the binding of antibodies and apo B-48 epitopes, the significant difference in apo B-48 
concentration may not have been detected. One of the suggestions is performing 
delipidation however this requires complex procedure and may cause protein degradation 
(Mills, Lane et al. 1984). Apo B-48 concentration in Sf <20 fraction in the studies in Chapter 
3 and 4 was determined by calculation rather than direct measurement. This may be the 
limitation of this study. 
The participants recruited in this study are from the older age range population. 
Thus it may not represent the variation or the extent of association between apo B-48 and 
other metabolic and anthropometric parameters in general population. However Australian 
population is an ageing society and most metabolic issues that impinge on CVD are usually 
evident from middle age range. In this respect, the studies included in this thesis are very 
useful. The small number of participants in the MetS group (Chapter 2) may overestimate 
the association between apo B-48 concentration and metabolic determinants. The limited 
number of participants (in HR and NR group) was also happened when conducting the 
postprandial study (Chapter 4). The difficulty in recruiting participants for this study due to 
the nature of the study (cross-over design with long day visits) may limit the power of the 
study. There were a number of considerable differences in apo B-48 response observed 
following the test meals but these were not statistically significant. If we had more study 
participants, these differences might become significant. We are also unable to gender-
match the subjects between groups in the postprandial study (Chapter 4). This would have 
enabled the identification of more subtle sex differences in lipid /apo B-48 metabolism that 
have been noted.   
 
5.7 Future studies 
This thesis for the first time provides evidence on the interactions between type of dietary 
fat, metabolic determinants and chylomicron size distribution in particular the dense 
fraction. This data is informative for research investigating postprandial lipaemia and CVD 
risk and may contribute to the method development in utilising fat tolerance tests in future 
research. 
 From our findings, with the same amount of fat ingested, the type of dietary fat 
affected the postprandial lipaemia suggesting the importance of the nature of ingested 
fatty acids on chylomicron response. The same amount of total fat in the SFA-rich meals but 
different chain lengths influenced the magnitude of postprandial lipaemia. Our findings also 
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showed that ingesting the same type and amount of dietary fat has differential effects on 
some normotriglyceridaemic subjects. Saturated fat is not a single entity and the merits in 
investigating the effect of SFA on health outcomes depend on the characteristics of the 
subjects consuming it, the dietary fatty acid composition within the meal, the food matrices 
and the comparators. This underscores the complex interactive effect of the nature of 
ingested fatty acids with genotype on chylomicron response and its risk for atherogenesis. 
We encourage further studies examining postprandial lipaemia following SFA challenge 
with different chain length and dose in a variety of metabolic conditions. 
 Studies are warranted to assess the association between small-sized chylomicron 
concentration with plasma inflammatory markers and lipid peroxidation and oxidative 
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